74 results on '"Novy E"'
Search Results
2. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France
- Author
-
Charmillon, A., Novy, E., Agrinier, N., Leone, M., Kimmoun, A., Levy, B., Demoré, B., Dellamonica, J., and Pulcini, C.
- Published
- 2016
- Full Text
- View/download PDF
3. Correction to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study
- Author
-
Sakr, Yasser, Ferrer, Ricard, Reinhart, Konrad, Beale, Richard, Rhodes, Andrew, Moreno, Rui, Timsit, Jean Francois, Brochard, Laurent, Thompson, B. Taylor, Rezende, Ederlon, Chiche, Jean Daniel, Auer, J., Schatzl, G., Mach, K., Gruber, H., Schreurs, E., Vander Laenen, M., Ceunen, H., Wauters, J., Francois, G., Deschamps, P., Castanares, D., Debels, D., Pierrakos, C., Vincent, J. L., Taccone, F., Vymazal, T., Gornik, I., Vujiaklija Brajkovic, A., Medici, R., Nielsen, J., Bendtsen, A., Siegel, H., Suonsyrjä, T., Hraech, S., Daviaux, F., Guillot, M., Castelain, V., Losser, R-R., Novy, E., Bouadma, L., Misset, B., Philippart, F., Mallat, J., Zogheib, E., Miclo, M., Teboul, J-L., Anguel, N., Darmon, M., Pham, T., Barberet, G., Plantefeve, G., Floccard, B., Kheladze, Z., Bloos, F., Faltlhauser, A., Helmes, T., Zacharowski, K., Meybohm, P., Schwarzkopf, K., Christ, M., Baumgaertel, M., John, S., Nentwich, J., Deja, M., Goldmann, A., Gottschalk, A., Honig, F., Siepe, B., Goebel, U., Lehmke, J., Behrens, S., Fiedler, K., Sagoschen, I., Riessen, R., Haap, M., Simon, Ph., Kaisers, U., Behrens, S., Niesen, M., Jaschinski, U., Hoersch, S., Jung, A., Allgaeuer, S., Haake, H., Lange, A., Papanikolaou, M., Balla, M., Giannakou, M., Soultati, I., Nikos, G., Koulouras, V., Kyriazopoulos, G., Gkika, D., Vlachogianni, G., Psaroulis, K., Mouloudi, E., Massa, E., Nichol, A., Meany, E., Motherway, C., Bellani, G., Pota, V., Schiavone, V., Girardis, M., Busani, S., Petrucci, N., Di Pasquale, R., Mazzini, P., Molin, A., Pellerano, G., Volta, C., Spadaro, S., Guarracino, F., Savioli, M., Pellis, T., Chinellato, N., Gatta, A., Cecchini, F., Raineri, S. M., Cortegiani, A., Kekstas, G., Karosas, V., Anguseva, T., Mitrev, Z., Beck, O., Cimic, N., Janssen, G., Bormans, L., Kuiper, M., Koopmans, K., Den Boer, S., de Groot, M., Dennesen, P., van den Bosch, J., Kluge, G., Mikaszewska-Sokolewicz, M., Lazowski, T., Chruscikowski, M., Machon, J., Adamik, B., Kübler, A., Wieczorek, A., Afonso, S., Matos, R., Catorze, N., Araujo, A., Costa, Z., Pais-de-Lacerda, A., Martins, I., Cardiga, R., Fernandes, L., Serra, I., Martinho, A., Tomescu, D., Popescu, M., Scarlatescu, E., Stoica, R., Macri, A., Filipescu, D., Rupnik, E., Tomic, V., Sifrer, F., Sole Violan, J., Ferrer Agüero, J. M., Izura, J., Monedero, P., de Cabo, C. Muños, Aguilar, G., Belda, F. J., Blanquer, J., Nives Carbonell, E., Lopez-Delgado, J-C., Aragon, C., Joya, C., Ortiz-Leyba, C., Fernandez Gonzalez, C. J., de la Torre-Prados, M-V., Puerto-Morlan, A., Araujo Aguilar, P., Tomás Marsilla, J. I., Vera Aratcoz, P., Olmo, A., Ferrer Roca, R., Catalan, R. M., Garcia Olivares, P., Albis, A., Alvarez, M., Corcoles Gonzalez, V., Gutierrez Rubio, J. M., Montoiro Allue, R., Rubio Mateo-Sidron, J., Hobrok, M., Cecconi, M., Di Tomasso, N., Raj, A., Szakmany, T., Srinivasa, L., Mathew, S., Ferguson, A., Blahut-Zugaj, M., Watters, M., Henderson, S., Sim, M., Csabi, P., O’Neill, O., Nutt, C., Humphreys, S., Bhowmick, K., Donnelly, A., O’Kane, S., Garfield, M., Jha, R., Unni, N., Gordon, A., Rubulotta, F., Ravi, K., Lunch, G., Franco, F., Higgs, D., Strandvik, G., Jonas, A., Hopkins, Ph., Hurst, T., Bellini, A., Balogun, O., Srinivasan, R., Ostermann, M., Alexander, P., McCalman, K., Bedford, J., Fulop, M., Brescia, G., Strachan, J., Meyer, J., Stotz, M., Brett, S., Zand, F., Nikandish, R., Hashemian, S., Jamaati, H., Alsheikhly, A. S., Almekhlafi, G., Albarrak, M., Maghrabi, A., Salahuddin, N., Aisa, T., Atalan, H. K., Sungur, M., Hegazi, M., Bauer, P., Mukkera, S., Fried, J., Barger, M., Gueret, R., Gonzalez, C., Lovesio, C., Dellera, Ch., Barrios, D., Leite Mendes, C., Gottardo, P., Caser, E., Santos, C., Carvalho, A., Teixeira, C., Samaniego, W., Whittle, S., Molano, D., Rojas, A., Guerra, K., Villamagua, B., Salgado-Yepez, E., Morocho, D., Remache-Vargas, N., Ñamendys-Silva, S., Rodriguez, D., Dominguez, G., Barraza, G., Bermudez-Aceves, E., Sanchez-Hurtado, L. A., Baltazar-Torres, J. A., Quispe Sierra, R., Chavez, C., von Osten, I., Van Haren, C., Smalley, N., Kol, M., Wong, H., Smith, R., Yu, L., Wu, X., Chao, L., Zhai, Q., Wu, D., Zhang, X., Jing, X., Bigornia, R., Ikeda-Maquiling, Y., Robles, J., Palo, J. E., Nguyen, T., Dao, C., Dixit, S., Gurjar, M., Reddy, P., Pravin, A., Simran, S., Ramakrishnan, N., Shetty, R., Udwadia, F., Faraz, M., Indraratna, K., Rajasinhe, J., and IC-GLOSSARI Investigators and ESICM Trials Group
- Published
- 2017
- Full Text
- View/download PDF
4. Implications of early respiratory support strategies on disease progression in critical COVID-19: a matched subanalysis of the prospective RISC-19-ICU cohort
- Author
-
Wendel Garcia, P, Aguirre-Bermeo, H, Buehler, P, Alfaro-Farias, M, Yuen, B, David, S, Tschoellitsch, T, Wengenmayer, T, Korsos, A, Fogagnolo, A, Kleger, G, Wu, M, Colombo, R, Turrini, F, Potalivo, A, Rezoagli, E, Rodriguez-Garcia, R, Castro, P, Lander-Azcona, A, Martin-Delgado, M, Lozano-Gomez, H, Ensner, R, Michot, M, Gehring, N, Schott, P, Siegemund, M, Merki, L, Wiegand, J, Jeitziner, M, Laube, M, Salomon, P, Hillgaertner, F, Dullenkopf, A, Ksouri, H, Cereghetti, S, Grazioli, S, Burkle, C, Marrel, J, Fleisch, I, Perez, M, Baltussen Weber, A, Ceruti, S, Marquardt, K, Hubner, T, Redecker, H, Studhalter, M, Stephan, M, Selz, D, Pietsch, U, Ristic, A, Heise, A, Meyer zu Bentrup, F, Franchitti Laurent, M, Fodor, P, Gaspert, T, Haberthuer, C, Colak, E, Heuberger, D, Fumeaux, T, Montomoli, J, Guerci, P, Schuepbach, R, Hilty, M, Roche-Campo, F, Algaba-Calderon, A, Apolo, J, Aslanidis, T, Babik, B, Boroli, F, Brem, J, Brenni, M, Brugger, S, Camen, G, Catena, E, Ceriani, R, Chau, I, Christ, A, Cogliati, C, Concha, P, Delahaye, G, Drvaric, I, Escos-Orta, J, Fabbri, S, Facondini, F, Filipovic, M, Gamez-Zapata, J, Gerecke, P, Gommers, D, Hillermann, T, Ince, C, Jenni-Moser, B, Jovic, M, Jurkolow, G, Klarer, A, Lambert, A, Laurent, J, Lavanchy, J, Lienhardt-Nobbe, B, Locher, P, Losser, M, Lussman, R, Magliocca, A, Margarit, A, Martinez, A, Mauri, R, Mayor-Vazquez, E, Meier, J, Moret-Bochatay, M, Murrone, M, Naon, D, Neff, T, Novy, E, Petersen, L, Pugin, J, Ramelet, A, Rilinger, J, Rimensberger, P, Sepulcri, M, Shaikh, K, Sieber, M, Simonini, M, Spadaro, S, Sridharan, G, Stahl, K, Staudacher, D, Taboada-Fraga, X, Tellez, A, Urech, S, Vitale, G, Vizmanos-Lamotte, G, Welte, T, Zalba-Etayo, B, Zellweger, N, Wendel Garcia P. D., Aguirre-Bermeo H., Buehler P. K., Alfaro-Farias M., Yuen B., David S., Tschoellitsch T., Wengenmayer T., Korsos A., Fogagnolo A., Kleger G. -R., Wu M. A., Colombo R., Turrini F., Potalivo A., Rezoagli E., Rodriguez-Garcia R., Castro P., Lander-Azcona A., Martin-Delgado M. C., Lozano-Gomez H., Ensner R., Michot M. P., Gehring N., Schott P., Siegemund M., Merki L., Wiegand J., Jeitziner M. M., Laube M., Salomon P., Hillgaertner F., Dullenkopf A., Ksouri H., Cereghetti S., Grazioli S., Burkle C., Marrel J., Fleisch I., Perez M. -H., Baltussen Weber A., Ceruti S., Marquardt K., Hubner T., Redecker H., Studhalter M., Stephan M., Selz D., Pietsch U., Ristic A., Heise A., Meyer zu Bentrup F., Franchitti Laurent M., Fodor P., Gaspert T., Haberthuer C., Colak E., Heuberger D. M., Fumeaux T., Montomoli J., Guerci P., Schuepbach R. A., Hilty M. P., Roche-Campo F., Algaba-Calderon A., Apolo J., Aslanidis T., Babik B., Boroli F., Brem J., Brenni M., Brugger S. D., Camen G., Catena E., Ceriani R., Chau I., Christ A., Cogliati C., Concha P., Delahaye G., Drvaric I., Escos-Orta J., Fabbri S., Facondini F., Filipovic M., Gamez-Zapata J., Gerecke P., Gommers D., Hillermann T., Ince C., Jenni-Moser B., Jovic M., Jurkolow G., Klarer A., Lambert A., Laurent J. -C., Lavanchy J., Lienhardt-Nobbe B., Locher P., Losser M. -R., Lussman R. F., Magliocca A., Margarit A., Martinez A., Mauri R., Mayor-Vazquez E., Meier J., Moret-Bochatay M., Murrone M., Naon D., Neff T., Novy E., Petersen L., Pugin J., Ramelet A. -S., Rilinger J., Rimensberger P. C., Sepulcri M., Shaikh K., Sieber M., Simonini M. S., Spadaro S., Sridharan G. O., Stahl K., Staudacher D. L., Taboada-Fraga X., Tellez A., Urech S., Vitale G., Vizmanos-Lamotte G., Welte T., Zalba-Etayo B., Zellweger N., Wendel Garcia, P, Aguirre-Bermeo, H, Buehler, P, Alfaro-Farias, M, Yuen, B, David, S, Tschoellitsch, T, Wengenmayer, T, Korsos, A, Fogagnolo, A, Kleger, G, Wu, M, Colombo, R, Turrini, F, Potalivo, A, Rezoagli, E, Rodriguez-Garcia, R, Castro, P, Lander-Azcona, A, Martin-Delgado, M, Lozano-Gomez, H, Ensner, R, Michot, M, Gehring, N, Schott, P, Siegemund, M, Merki, L, Wiegand, J, Jeitziner, M, Laube, M, Salomon, P, Hillgaertner, F, Dullenkopf, A, Ksouri, H, Cereghetti, S, Grazioli, S, Burkle, C, Marrel, J, Fleisch, I, Perez, M, Baltussen Weber, A, Ceruti, S, Marquardt, K, Hubner, T, Redecker, H, Studhalter, M, Stephan, M, Selz, D, Pietsch, U, Ristic, A, Heise, A, Meyer zu Bentrup, F, Franchitti Laurent, M, Fodor, P, Gaspert, T, Haberthuer, C, Colak, E, Heuberger, D, Fumeaux, T, Montomoli, J, Guerci, P, Schuepbach, R, Hilty, M, Roche-Campo, F, Algaba-Calderon, A, Apolo, J, Aslanidis, T, Babik, B, Boroli, F, Brem, J, Brenni, M, Brugger, S, Camen, G, Catena, E, Ceriani, R, Chau, I, Christ, A, Cogliati, C, Concha, P, Delahaye, G, Drvaric, I, Escos-Orta, J, Fabbri, S, Facondini, F, Filipovic, M, Gamez-Zapata, J, Gerecke, P, Gommers, D, Hillermann, T, Ince, C, Jenni-Moser, B, Jovic, M, Jurkolow, G, Klarer, A, Lambert, A, Laurent, J, Lavanchy, J, Lienhardt-Nobbe, B, Locher, P, Losser, M, Lussman, R, Magliocca, A, Margarit, A, Martinez, A, Mauri, R, Mayor-Vazquez, E, Meier, J, Moret-Bochatay, M, Murrone, M, Naon, D, Neff, T, Novy, E, Petersen, L, Pugin, J, Ramelet, A, Rilinger, J, Rimensberger, P, Sepulcri, M, Shaikh, K, Sieber, M, Simonini, M, Spadaro, S, Sridharan, G, Stahl, K, Staudacher, D, Taboada-Fraga, X, Tellez, A, Urech, S, Vitale, G, Vizmanos-Lamotte, G, Welte, T, Zalba-Etayo, B, Zellweger, N, Wendel Garcia P. D., Aguirre-Bermeo H., Buehler P. K., Alfaro-Farias M., Yuen B., David S., Tschoellitsch T., Wengenmayer T., Korsos A., Fogagnolo A., Kleger G. -R., Wu M. A., Colombo R., Turrini F., Potalivo A., Rezoagli E., Rodriguez-Garcia R., Castro P., Lander-Azcona A., Martin-Delgado M. C., Lozano-Gomez H., Ensner R., Michot M. P., Gehring N., Schott P., Siegemund M., Merki L., Wiegand J., Jeitziner M. M., Laube M., Salomon P., Hillgaertner F., Dullenkopf A., Ksouri H., Cereghetti S., Grazioli S., Burkle C., Marrel J., Fleisch I., Perez M. -H., Baltussen Weber A., Ceruti S., Marquardt K., Hubner T., Redecker H., Studhalter M., Stephan M., Selz D., Pietsch U., Ristic A., Heise A., Meyer zu Bentrup F., Franchitti Laurent M., Fodor P., Gaspert T., Haberthuer C., Colak E., Heuberger D. M., Fumeaux T., Montomoli J., Guerci P., Schuepbach R. A., Hilty M. P., Roche-Campo F., Algaba-Calderon A., Apolo J., Aslanidis T., Babik B., Boroli F., Brem J., Brenni M., Brugger S. D., Camen G., Catena E., Ceriani R., Chau I., Christ A., Cogliati C., Concha P., Delahaye G., Drvaric I., Escos-Orta J., Fabbri S., Facondini F., Filipovic M., Gamez-Zapata J., Gerecke P., Gommers D., Hillermann T., Ince C., Jenni-Moser B., Jovic M., Jurkolow G., Klarer A., Lambert A., Laurent J. -C., Lavanchy J., Lienhardt-Nobbe B., Locher P., Losser M. -R., Lussman R. F., Magliocca A., Margarit A., Martinez A., Mauri R., Mayor-Vazquez E., Meier J., Moret-Bochatay M., Murrone M., Naon D., Neff T., Novy E., Petersen L., Pugin J., Ramelet A. -S., Rilinger J., Rimensberger P. C., Sepulcri M., Shaikh K., Sieber M., Simonini M. S., Spadaro S., Sridharan G. O., Stahl K., Staudacher D. L., Taboada-Fraga X., Tellez A., Urech S., Vitale G., Vizmanos-Lamotte G., Welte T., Zalba-Etayo B., and Zellweger N.
- Abstract
Background: Uncertainty about the optimal respiratory support strategies in critically ill COVID-19 patients is widespread. While the risks and benefits of noninvasive techniques versus early invasive mechanical ventilation (IMV) are intensely debated, actual evidence is lacking. We sought to assess the risks and benefits of different respiratory support strategies, employed in intensive care units during the first months of the COVID-19 pandemic on intubation and intensive care unit (ICU) mortality rates. Methods: Subanalysis of a prospective, multinational registry of critically ill COVID-19 patients. Patients were subclassified into standard oxygen therapy ≥10 L/min (SOT), high-flow oxygen therapy (HFNC), noninvasive positive-pressure ventilation (NIV), and early IMV, according to the respiratory support strategy employed at the day of admission to ICU. Propensity score matching was performed to ensure comparability between groups. Results: Initially, 1421 patients were assessed for possible study inclusion. Of these, 351 patients (85 SOT, 87 HFNC, 87 NIV, and 92 IMV) remained eligible for full analysis after propensity score matching. 55% of patients initially receiving noninvasive respiratory support required IMV. The intubation rate was lower in patients initially ventilated with HFNC and NIV compared to those who received SOT (SOT: 64%, HFNC: 52%, NIV: 49%, p = 0.025). Compared to the other respiratory support strategies, NIV was associated with a higher overall ICU mortality (SOT: 18%, HFNC: 20%, NIV: 37%, IMV: 25%, p = 0.016). Conclusion: In this cohort of critically ill patients with COVID-19, a trial of HFNC appeared to be the most balanced initial respiratory support strategy, given the reduced intubation rate and comparable ICU mortality rate. Nonetheless, considering the uncertainty and stress associated with the COVID-19 pandemic, SOT and early IMV represented safe initial respiratory support strategies. The presented findings, in
- Published
- 2021
5. Machine learning using the extreme gradient boosting (XGBoost) algorithm predicts 5-day delta of SOFA score at ICU admission in COVID-19 patients
- Author
-
Montomoli, J, Romeo, L, Moccia, S, Bernardini, M, Migliorelli, L, Berardini, D, Donati, A, Carsetti, A, Bocci, M, Wendel Garcia, P, Fumeaux, T, Guerci, P, Schupbach, R, Ince, C, Frontoni, E, Hilty, M, Alfaro-Farias, M, Vizmanos-Lamotte, G, Tschoellitsch, T, Meier, J, Aguirre-Bermeo, H, Apolo, J, Martinez, A, Jurkolow, G, Delahaye, G, Novy, E, Losser, M, Wengenmayer, T, Rilinger, J, Staudacher, D, David, S, Welte, T, Stahl, K, Pavlos, A, Aslanidis, T, Korsos, A, Babik, B, Nikandish, R, Rezoagli, E, Giacomini, M, Nova, A, Fogagnolo, A, Spadaro, S, Ceriani, R, Murrone, M, Wu, M, Cogliati, C, Colombo, R, Catena, E, Turrini, F, Simonini, M, Fabbri, S, Potalivo, A, Facondini, F, Gangitano, G, Perin, T, Grazia Bocci, M, Antonelli, M, Gommers, D, Rodriguez-Garcia, R, Gamez-Zapata, J, Taboada-Fraga, X, Castro, P, Tellez, A, Lander-Azcona, A, Escos-Orta, J, Martin-Delgado, M, Algaba-Calderon, A, Franch-Llasat, D, Roche-Campo, F, Lozano-Gomez, H, Zalba-Etayo, B, Michot, M, Klarer, A, Ensner, R, Schott, P, Urech, S, Zellweger, N, Merki, L, Lambert, A, Laube, M, Jeitziner, M, Jenni-Moser, B, Wiegand, J, Yuen, B, Lienhardt-Nobbe, B, Westphalen, A, Salomon, P, Drvaric, I, Hillgaertner, F, Sieber, M, Dullenkopf, A, Petersen, L, Chau, I, Ksouri, H, Sridharan, G, Cereghetti, S, Boroli, F, Pugin, J, Grazioli, S, Rimensberger, P, Burkle, C, Marrel, J, Brenni, M, Fleisch, I, Lavanchy, J, Perez, M, Ramelet, A, Weber, A, Gerecke, P, Christ, A, Ceruti, S, Glotta, A, Marquardt, K, Shaikh, K, Hubner, T, Neff, T, Redecker, H, Moret-Bochatay, M, Bentrup, F, Studhalter, M, Stephan, M, Brem, J, Gehring, N, Selz, D, Naon, D, Kleger, G, Pietsch, U, Filipovic, M, Ristic, A, Sepulcri, M, Heise, A, Franchitti Laurent, M, Laurent, J, Schuepbach, R, Heuberger, D, Buhler, P, Brugger, S, Fodor, P, Locher, P, Camen, G, Gaspert, T, Jovic, M, Haberthuer, C, Lussman, R, Colak, E, Montomoli J., Romeo L., Moccia S., Bernardini M., Migliorelli L., Berardini D., Donati A., Carsetti A., Bocci M. G., Wendel Garcia P. D., Fumeaux T., Guerci P., Schupbach R. A., Ince C., Frontoni E., Hilty M. P., Alfaro-Farias M., Vizmanos-Lamotte G., Tschoellitsch T., Meier J., Aguirre-Bermeo H., Apolo J., Martinez A., Jurkolow G., Delahaye G., Novy E., Losser M. -R., Wengenmayer T., Rilinger J., Staudacher D. L., David S., Welte T., Stahl K., Pavlos A., Aslanidis T., Korsos A., Babik B., Nikandish R., Rezoagli E., Giacomini M., Nova A., Fogagnolo A., Spadaro S., Ceriani R., Murrone M., Wu M. A., Cogliati C., Colombo R., Catena E., Turrini F., Simonini M. S., Fabbri S., Potalivo A., Facondini F., Gangitano G., Perin T., Grazia Bocci M., Antonelli M., Gommers D., Rodriguez-Garcia R., Gamez-Zapata J., Taboada-Fraga X., Castro P., Tellez A., Lander-Azcona A., Escos-Orta J., Martin-Delgado M. C., Algaba-Calderon A., Franch-Llasat D., Roche-Campo F., Lozano-Gomez H., Zalba-Etayo B., Michot M. P., Klarer A., Ensner R., Schott P., Urech S., Zellweger N., Merki L., Lambert A., Laube M., Jeitziner M. M., Jenni-Moser B., Wiegand J., Yuen B., Lienhardt-Nobbe B., Westphalen A., Salomon P., Drvaric I., Hillgaertner F., Sieber M., Dullenkopf A., Petersen L., Chau I., Ksouri H., Sridharan G. O., Cereghetti S., Boroli F., Pugin J., Grazioli S., Rimensberger P. C., Burkle C., Marrel J., Brenni M., Fleisch I., Lavanchy J., Perez M. -H., Ramelet A. -S., Weber A. B., Gerecke P., Christ A., Ceruti S., Glotta A., Marquardt K., Shaikh K., Hubner T., Neff T., Redecker H., Moret-Bochatay M., Bentrup F. Z., Studhalter M., Stephan M., Brem J., Gehring N., Selz D., Naon D., Kleger G. -R., Pietsch U., Filipovic M., Ristic A., Sepulcri M., Heise A., Franchitti Laurent M., Laurent J. -C., Schuepbach R., Heuberger D., Buhler P., Brugger S., Fodor P., Locher P., Camen G., Gaspert T., Jovic M., Haberthuer C., Lussman R. F., Colak E., Montomoli, J, Romeo, L, Moccia, S, Bernardini, M, Migliorelli, L, Berardini, D, Donati, A, Carsetti, A, Bocci, M, Wendel Garcia, P, Fumeaux, T, Guerci, P, Schupbach, R, Ince, C, Frontoni, E, Hilty, M, Alfaro-Farias, M, Vizmanos-Lamotte, G, Tschoellitsch, T, Meier, J, Aguirre-Bermeo, H, Apolo, J, Martinez, A, Jurkolow, G, Delahaye, G, Novy, E, Losser, M, Wengenmayer, T, Rilinger, J, Staudacher, D, David, S, Welte, T, Stahl, K, Pavlos, A, Aslanidis, T, Korsos, A, Babik, B, Nikandish, R, Rezoagli, E, Giacomini, M, Nova, A, Fogagnolo, A, Spadaro, S, Ceriani, R, Murrone, M, Wu, M, Cogliati, C, Colombo, R, Catena, E, Turrini, F, Simonini, M, Fabbri, S, Potalivo, A, Facondini, F, Gangitano, G, Perin, T, Grazia Bocci, M, Antonelli, M, Gommers, D, Rodriguez-Garcia, R, Gamez-Zapata, J, Taboada-Fraga, X, Castro, P, Tellez, A, Lander-Azcona, A, Escos-Orta, J, Martin-Delgado, M, Algaba-Calderon, A, Franch-Llasat, D, Roche-Campo, F, Lozano-Gomez, H, Zalba-Etayo, B, Michot, M, Klarer, A, Ensner, R, Schott, P, Urech, S, Zellweger, N, Merki, L, Lambert, A, Laube, M, Jeitziner, M, Jenni-Moser, B, Wiegand, J, Yuen, B, Lienhardt-Nobbe, B, Westphalen, A, Salomon, P, Drvaric, I, Hillgaertner, F, Sieber, M, Dullenkopf, A, Petersen, L, Chau, I, Ksouri, H, Sridharan, G, Cereghetti, S, Boroli, F, Pugin, J, Grazioli, S, Rimensberger, P, Burkle, C, Marrel, J, Brenni, M, Fleisch, I, Lavanchy, J, Perez, M, Ramelet, A, Weber, A, Gerecke, P, Christ, A, Ceruti, S, Glotta, A, Marquardt, K, Shaikh, K, Hubner, T, Neff, T, Redecker, H, Moret-Bochatay, M, Bentrup, F, Studhalter, M, Stephan, M, Brem, J, Gehring, N, Selz, D, Naon, D, Kleger, G, Pietsch, U, Filipovic, M, Ristic, A, Sepulcri, M, Heise, A, Franchitti Laurent, M, Laurent, J, Schuepbach, R, Heuberger, D, Buhler, P, Brugger, S, Fodor, P, Locher, P, Camen, G, Gaspert, T, Jovic, M, Haberthuer, C, Lussman, R, Colak, E, Montomoli J., Romeo L., Moccia S., Bernardini M., Migliorelli L., Berardini D., Donati A., Carsetti A., Bocci M. G., Wendel Garcia P. D., Fumeaux T., Guerci P., Schupbach R. A., Ince C., Frontoni E., Hilty M. P., Alfaro-Farias M., Vizmanos-Lamotte G., Tschoellitsch T., Meier J., Aguirre-Bermeo H., Apolo J., Martinez A., Jurkolow G., Delahaye G., Novy E., Losser M. -R., Wengenmayer T., Rilinger J., Staudacher D. L., David S., Welte T., Stahl K., Pavlos A., Aslanidis T., Korsos A., Babik B., Nikandish R., Rezoagli E., Giacomini M., Nova A., Fogagnolo A., Spadaro S., Ceriani R., Murrone M., Wu M. A., Cogliati C., Colombo R., Catena E., Turrini F., Simonini M. S., Fabbri S., Potalivo A., Facondini F., Gangitano G., Perin T., Grazia Bocci M., Antonelli M., Gommers D., Rodriguez-Garcia R., Gamez-Zapata J., Taboada-Fraga X., Castro P., Tellez A., Lander-Azcona A., Escos-Orta J., Martin-Delgado M. C., Algaba-Calderon A., Franch-Llasat D., Roche-Campo F., Lozano-Gomez H., Zalba-Etayo B., Michot M. P., Klarer A., Ensner R., Schott P., Urech S., Zellweger N., Merki L., Lambert A., Laube M., Jeitziner M. M., Jenni-Moser B., Wiegand J., Yuen B., Lienhardt-Nobbe B., Westphalen A., Salomon P., Drvaric I., Hillgaertner F., Sieber M., Dullenkopf A., Petersen L., Chau I., Ksouri H., Sridharan G. O., Cereghetti S., Boroli F., Pugin J., Grazioli S., Rimensberger P. C., Burkle C., Marrel J., Brenni M., Fleisch I., Lavanchy J., Perez M. -H., Ramelet A. -S., Weber A. B., Gerecke P., Christ A., Ceruti S., Glotta A., Marquardt K., Shaikh K., Hubner T., Neff T., Redecker H., Moret-Bochatay M., Bentrup F. Z., Studhalter M., Stephan M., Brem J., Gehring N., Selz D., Naon D., Kleger G. -R., Pietsch U., Filipovic M., Ristic A., Sepulcri M., Heise A., Franchitti Laurent M., Laurent J. -C., Schuepbach R., Heuberger D., Buhler P., Brugger S., Fodor P., Locher P., Camen G., Gaspert T., Jovic M., Haberthuer C., Lussman R. F., and Colak E.
- Abstract
Background: Accurate risk stratification of critically ill patients with coronavirus disease 2019 (COVID-19) is essential for optimizing resource allocation, delivering targeted interventions, and maximizing patient survival probability. Machine learning (ML) techniques are attracting increased interest for the development of prediction models as they excel in the analysis of complex signals in data-rich environments such as critical care. Methods: We retrieved data on patients with COVID-19 admitted to an intensive care unit (ICU) between March and October 2020 from the RIsk Stratification in COVID-19 patients in the Intensive Care Unit (RISC-19-ICU) registry. We applied the Extreme Gradient Boosting (XGBoost) algorithm to the data to predict as a binary outcome the increase or decrease in patients’ Sequential Organ Failure Assessment (SOFA) score on day 5 after ICU admission. The model was iteratively cross-validated in different subsets of the study cohort. Results: The final study population consisted of 675 patients. The XGBoost model correctly predicted a decrease in SOFA score in 320/385 (83%) critically ill COVID-19 patients, and an increase in the score in 210/290 (72%) patients. The area under the mean receiver operating characteristic curve for XGBoost was significantly higher than that for the logistic regression model (0.86 vs. 0.69, P < 0.01 [paired t-test with 95% confidence interval]). Conclusions: The XGBoost model predicted the change in SOFA score in critically ill COVID-19 patients admitted to the ICU and can guide clinical decision support systems (CDSSs) aimed at optimizing available resources.
- Published
- 2021
6. Implications of early respiratory support strategies on disease progression in critical COVID-19: a matched subanalysis of the prospective RISC-19-ICU cohort
- Author
-
Wendel Garcia P. D., Aguirre-Bermeo H., Buehler P. K., Alfaro-Farias M., Yuen B., David S., Tschoellitsch T., Wengenmayer T., Korsos A., Fogagnolo A., Kleger G. -R., Wu M. A., Colombo R., Turrini F., Potalivo A., Rezoagli E., Rodriguez-Garcia R., Castro P., Lander-Azcona A., Martin-Delgado M. C., Lozano-Gomez H., Ensner R., Michot M. P., Gehring N., Schott P., Siegemund M., Merki L., Wiegand J., Jeitziner M. M., Laube M., Salomon P., Hillgaertner F., Dullenkopf A., Ksouri H., Cereghetti S., Grazioli S., Burkle C., Marrel J., Fleisch I., Perez M. -H., Baltussen Weber A., Ceruti S., Marquardt K., Hubner T., Redecker H., Studhalter M., Stephan M., Selz D., Pietsch U., Ristic A., Heise A., Meyer zu Bentrup F., Franchitti Laurent M., Fodor P., Gaspert T., Haberthuer C., Colak E., Heuberger D. M., Fumeaux T., Montomoli J., Guerci P., Schuepbach R. A., Hilty M. P., Roche-Campo F., Algaba-Calderon A., Apolo J., Aslanidis T., Babik B., Boroli F., Brem J., Brenni M., Brugger S. D., Camen G., Catena E., Ceriani R., Chau I., Christ A., Cogliati C., Concha P., Delahaye G., Drvaric I., Escos-Orta J., Fabbri S., Facondini F., Filipovic M., Gamez-Zapata J., Gerecke P., Gommers D., Hillermann T., Ince C., Jenni-Moser B., Jovic M., Jurkolow G., Klarer A., Lambert A., Laurent J. -C., Lavanchy J., Lienhardt-Nobbe B., Locher P., Losser M. -R., Lussman R. F., Magliocca A., Margarit A., Martinez A., Mauri R., Mayor-Vazquez E., Meier J., Moret-Bochatay M., Murrone M., Naon D., Neff T., Novy E., Petersen L., Pugin J., Ramelet A. -S., Rilinger J., Rimensberger P. C., Sepulcri M., Shaikh K., Sieber M., Simonini M. S., Spadaro S., Sridharan G. O., Stahl K., Staudacher D. L., Taboada-Fraga X., Tellez A., Urech S., Vitale G., Vizmanos-Lamotte G., Welte T., Zalba-Etayo B., Zellweger N., Graduate School, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, AII - Inflammatory diseases, RISC-19-ICU Investigators, Wendel Garcia, P.D., Aguirre-Bermeo, H., Buehler, P.K., Alfaro-Farias, M., Yuen, B., David, S., Tschoellitsch, T., Wengenmayer, T., Korsos, A., Fogagnolo, A., Kleger, G.R., Wu, M.A., Colombo, R., Turrini, F., Potalivo, A., Rezoagli, E., Rodríguez-García, R., Castro, P., Lander-Azcona, A., Martín-Delgado, M.C., Lozano-Gómez, H., Ensner, R., Michot, M.P., Gehring, N., Schott, P., Siegemund, M., Merki, L., Wiegand, J., Jeitziner, M.M., Laube, M., Salomon, P., Hillgaertner, F., Dullenkopf, A., Ksouri, H., Cereghetti, S., Grazioli, S., Bürkle, C., Marrel, J., Fleisch, I., Perez, M.H., Baltussen Weber, A., Ceruti, S., Marquardt, K., Hübner, T., Redecker, H., Studhalter, M., Stephan, M., Selz, D., Pietsch, U., Ristic, A., Heise, A., Meyer Zu Bentrup, F., Franchitti Laurent, M., Fodor, P., Gaspert, T., Haberthuer, C., Colak, E., Heuberger, D.M., Fumeaux, T., Montomoli, J., Guerci, P., Schuepbach, R.A., Hilty, M.P., Roche-Campo, F., Algaba-Calderon, A., Apolo, J., Aslanidis, T., Babik, B., Boroli, F., Brem, J., Brenni, M., Brugger, S.D., Camen, G., Catena, E., Ceriani, R., Chau, I., Christ, A., Cogliati, C., Concha, P., Delahaye, G., Drvaric, I., Escós-Orta, J., Fabbri, S., Facondini, F., Filipovic, M., Gámez-Zapata, J., Gerecke, P., Gommers, D., Hillermann, T., Ince, C., Jenni-Moser, B., Jovic, M., Jurkolow, G., Klarer, A., Lambert, A., Laurent, J.C., Lavanchy, J., Lienhardt-Nobbe, B., Locher, P., Losser, M.R., Lussman, R.F., Magliocca, A., Margarit, A., Martínez, A., Mauri, R., Mayor-Vázquez, E., Meier, J., Moret-Bochatay, M., Murrone, M., Naon, D., Neff, T., Novy, E., Petersen, L., Pugin, J., Ramelet, A.S., Rilinger, J., Rimensberger, P.C., Sepulcri, M., Shaikh, K., Sieber, M., Simonini, M.S., Spadaro, S., Sridharan, G.O., Stahl, K., Staudacher, D.L., Taboada-Fraga, X., Tellez, A., Urech, S., Vitale, G., Vizmanos-Lamotte, G., Welte, T., Zalba-Etayo, B., Zellweger, N., Wendel Garcia, P, Aguirre-Bermeo, H, Buehler, P, Alfaro-Farias, M, Yuen, B, David, S, Tschoellitsch, T, Wengenmayer, T, Korsos, A, Fogagnolo, A, Kleger, G, Wu, M, Colombo, R, Turrini, F, Potalivo, A, Rezoagli, E, Rodriguez-Garcia, R, Castro, P, Lander-Azcona, A, Martin-Delgado, M, Lozano-Gomez, H, Ensner, R, Michot, M, Gehring, N, Schott, P, Siegemund, M, Merki, L, Wiegand, J, Jeitziner, M, Laube, M, Salomon, P, Hillgaertner, F, Dullenkopf, A, Ksouri, H, Cereghetti, S, Grazioli, S, Burkle, C, Marrel, J, Fleisch, I, Perez, M, Baltussen Weber, A, Ceruti, S, Marquardt, K, Hubner, T, Redecker, H, Studhalter, M, Stephan, M, Selz, D, Pietsch, U, Ristic, A, Heise, A, Meyer zu Bentrup, F, Franchitti Laurent, M, Fodor, P, Gaspert, T, Haberthuer, C, Colak, E, Heuberger, D, Fumeaux, T, Montomoli, J, Guerci, P, Schuepbach, R, Hilty, M, Roche-Campo, F, Algaba-Calderon, A, Apolo, J, Aslanidis, T, Babik, B, Boroli, F, Brem, J, Brenni, M, Brugger, S, Camen, G, Catena, E, Ceriani, R, Chau, I, Christ, A, Cogliati, C, Concha, P, Delahaye, G, Drvaric, I, Escos-Orta, J, Fabbri, S, Facondini, F, Filipovic, M, Gamez-Zapata, J, Gerecke, P, Gommers, D, Hillermann, T, Ince, C, Jenni-Moser, B, Jovic, M, Jurkolow, G, Klarer, A, Lambert, A, Laurent, J, Lavanchy, J, Lienhardt-Nobbe, B, Locher, P, Losser, M, Lussman, R, Magliocca, A, Margarit, A, Martinez, A, Mauri, R, Mayor-Vazquez, E, Meier, J, Moret-Bochatay, M, Murrone, M, Naon, D, Neff, T, Novy, E, Petersen, L, Pugin, J, Ramelet, A, Rilinger, J, Rimensberger, P, Sepulcri, M, Shaikh, K, Sieber, M, Simonini, M, Spadaro, S, Sridharan, G, Stahl, K, Staudacher, D, Taboada-Fraga, X, Tellez, A, Urech, S, Vitale, G, Vizmanos-Lamotte, G, Welte, T, Zalba-Etayo, B, Zellweger, N, and Intensive Care
- Subjects
Male ,ARDS ,Time Factors ,medicine.medical_treatment ,Old age ,Critical Care and Intensive Care Medicine ,law.invention ,0302 clinical medicine ,law ,Oxygen therapy ,Noninvasive mechanical ventilation ,Intubation ,030212 general & internal medicine ,Hospital Mortality ,Prospective Studies ,Registries ,Prospective cohort study ,610 Medicine & health ,Unitats de cures intensives ,Intensive care units ,Medical emergencies. Critical care. Intensive care. First aid ,Middle Aged ,Intensive care unit ,Intensive Care Units ,Treatment Outcome ,Vellesa ,High flow oxygen therapy ,Disease Progression ,Female ,Standard oxygen therapy ,medicine.medical_specialty ,Respiratory Therapy ,Critical Illness ,NO ,03 medical and health sciences ,Intensive care ,medicine ,Humans ,Invasive mechanical ventilation ,Critically ill ,Patient self-inflicted lung injury ,Aged ,Retrospective Studies ,Mechanical ventilation ,COVID-19/mortality ,COVID-19/therapy ,Critical Illness/mortality ,Critical Illness/therapy ,Respiratory Therapy/methods ,Respiratory Therapy/statistics & numerical data ,COVID-19 ,Respiratory support ,business.industry ,RC86-88.9 ,Research ,Retrospective cohort study ,medicine.disease ,Malalts en estat crític ,030228 respiratory system ,Emergency medicine ,business - Abstract
Background Uncertainty about the optimal respiratory support strategies in critically ill COVID-19 patients is widespread. While the risks and benefits of noninvasive techniques versus early invasive mechanical ventilation (IMV) are intensely debated, actual evidence is lacking. We sought to assess the risks and benefits of different respiratory support strategies, employed in intensive care units during the first months of the COVID-19 pandemic on intubation and intensive care unit (ICU) mortality rates. Methods Subanalysis of a prospective, multinational registry of critically ill COVID-19 patients. Patients were subclassified into standard oxygen therapy ≥10 L/min (SOT), high-flow oxygen therapy (HFNC), noninvasive positive-pressure ventilation (NIV), and early IMV, according to the respiratory support strategy employed at the day of admission to ICU. Propensity score matching was performed to ensure comparability between groups. Results Initially, 1421 patients were assessed for possible study inclusion. Of these, 351 patients (85 SOT, 87 HFNC, 87 NIV, and 92 IMV) remained eligible for full analysis after propensity score matching. 55% of patients initially receiving noninvasive respiratory support required IMV. The intubation rate was lower in patients initially ventilated with HFNC and NIV compared to those who received SOT (SOT: 64%, HFNC: 52%, NIV: 49%, p = 0.025). Compared to the other respiratory support strategies, NIV was associated with a higher overall ICU mortality (SOT: 18%, HFNC: 20%, NIV: 37%, IMV: 25%, p = 0.016). Conclusion In this cohort of critically ill patients with COVID-19, a trial of HFNC appeared to be the most balanced initial respiratory support strategy, given the reduced intubation rate and comparable ICU mortality rate. Nonetheless, considering the uncertainty and stress associated with the COVID-19 pandemic, SOT and early IMV represented safe initial respiratory support strategies. The presented findings, in agreement with classic ARDS literature, suggest that NIV should be avoided whenever possible due to the elevated ICU mortality risk.
- Published
- 2021
- Full Text
- View/download PDF
7. Neurological complications of infective endocarditis: New breakthroughs in diagnosis and management
- Author
-
Novy, E., Sonneville, R., Mazighi, M., Klein, I.F., Mariotte, E., Mourvillier, B., Bouadma, L., and Wolff, M.
- Published
- 2013
- Full Text
- View/download PDF
8. Choc hémorragique : aspects physiopathologiques et prise en charge hémodynamique
- Author
-
Novy, E. and Levy, B.
- Published
- 2015
- Full Text
- View/download PDF
9. COL 1-05 - Antibioperf : enquête nationale sur les pratiques de perfusion des bêta-lactamines et leurs dosages chez un patient en sepsis sévère
- Author
-
Charmillon, A., Novy, E., Agrinier, N., Leone, M., Kimmoun, A., Levy, B., Demoré, B., Dellamonica, J., and Pulcini, C.
- Published
- 2016
- Full Text
- View/download PDF
10. Erratum to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC‐GLOSSARI): a multicenter, multinational, 14-day inception cohort study (Intensive Care Medicine, (2016), 42, 5, (953), 10.1007/s00134-016-4317-4)
- Author
-
Auer J., Auer, J, Schatzl, G, Mach, K, Gruber, H, Schreurs, E, Vander Laenen, M, Ceunen, H, Wauters, J, Francois, G, Deschamps, P, Castanares, D, Debels, D, Pierrakos, C, Vincent, J, Taccone, F, Vymazal, T, Gornik, I, Vujiaklija Brajkovic, A, Medici, R, Nielsen, J, Bendtsen, A, Siegel, H, Suonsyrja, T, Hraech, S, Chiche, J, Daviaux, F, Guillot, M, Castelain, V, Losser, R, Novy, E, Timsit, J, Bouadma, L, Misset, B, Philippart, F, Mallat, J, Zogheib, E, Miclo, M, Teboul, J, Anguel, N, Darmon, M, Pham, T, Barberet, G, Plantefeve, G, Floccard, B, Kheladze, Z, Reinhart, K, Sakr, Y, Bloos, F, Faltlhauser, A, Helmes, T, Zacharowski, K, Meybohm, P, Schwarzkopf, K, Christ, M, Baumgaertel, M, John, S, Nentwich, J, Deja, M, Goldmann, A, Gottschalk, A, Honig, F, Siepe, B, Goebel, U, Lehmke, J, Behrens, S, Fiedler, K, Sagoschen, I, Riessen, R, Haap, M, Simon, P, Kaisers, U, Niesen, M, Jaschinski, U, Hoersch, S, Jung, A, Allgaeuer, S, Haake, H, Lange, A, Papanikolaou, M, Balla, M, Giannakou, M, Soultati, I, Nikos, G, Koulouras, V, Kyriazopoulos, G, Gkika, D, Vlachogianni, G, Psaroulis, K, Mouloudi, E, Massa, E, Nichol, A, Meany, E, Motherway, C, Bellani, G, Pota, V, Schiavone, V, Girardis, M, Busani, S, Petrucci, N, Di Pasquale, R, Mazzini, P, Molin, A, Pellerano, G, Volta, C, Spadaro, S, Guarracino, F, Savioli, M, Pellis, T, Chinellato, N, Gatta, A, Cecchini, F, Raineri, S, Cortegiani, A, Kekstas, G, Karosas, V, Anguseva, T, Mitrev, Z, Beck, O, Cimic, N, Janssen, G, Bormans, L, Kuiper, M, Koopmans, K, Den Boer, S, de Groot, M, Dennesen, P, van den Bosch, J, Kluge, G, Mikaszewska-Sokolewicz, M, Lazowski, T, Chruscikowski, M, Machon, J, Adamik, B, Kubler, A, Wieczorek, A, Afonso, S, Matos, R, Catorze, N, Araujo, A, Costa, Z, Pais-de-Lacerda, A, Martins, I, Cardiga, R, Fernandes, L, Serra, I, Martinho, A, Tomescu, D, Popescu, M, Scarlatescu, E, Stoica, R, Macri, A, Filipescu, D, Rupnik, E, Tomic, V, Sifrer, F, Sole Violan, J, Ferrer Aguero, J, Izura, B, Monedero, P, Munos de Cabo, C, Aguilar, G, Belda, F, Blanquer, J, Nives Carbonell, E, Lopez-Delgado, J, Aragon, C, Joya, C, Ortiz-Leyba, C, Fernandez Gonzalez, C, de la Torre-Prados, M, Puerto-Morlan, A, Araujo Aguilar, P, Tomas Marsilla, J, Vera Aratcoz, P, Olmo, A, Ferrer Roca, R, Catalan, R, Garcia Olivares, P, Albis, A, Alvarez, M, Corcoles Gonzalez, V, Gutierrez Rubio, J, Montoiro Allue, R, Rubio Mateo-Sidron, J, Hobrok, M, Cecconi, M, Di Tomasso, N, Raj, A, Szakmany, T, Srinivasa, L, Mathew, S, Ferguson, A, Blahut-Zugaj, M, Watters, M, Henderson, S, Sim, M, Csabi, P, O'Neill, O, Nutt, C, Humphreys, S, Bhowmick, K, Donnelly, A, O'Kane, S, Garfield, M, Jha, R, Unni, N, Gordon, A, Rubulotta, F, Ravi, K, Lunch, G, Franco, F, Higgs, D, Strandvik, G, Jonas, A, Hopkins, P, Hurst, T, Bellini, A, Balogun, O, Srinivasan, R, Ostermann, M, Alexander, P, Mccalman, K, Bedford, J, Fulop, M, Brescia, G, Strachan, J, Meyer, J, Stotz, M, Brett, S, Zand, F, Nikandish, R, Hashemian, S, Jamaati, H, Alsheikhly, A, Almekhlafi, G, Albarrak, M, Maghrabi, A, Salahuddin, N, Aisa, T, Atalan, H, Sungur, M, Hegazi, M, Bauer, P, Mukkera, S, Fried, J, Barger, M, Gueret, R, Gonzalez, C, Lovesio, C, Dellera, C, Barrios, D, Leite Mendes, C, Gottardo, P, Caser, E, Santos, C, Carvalho, A, Teixeira, C, Samaniego, W, Whittle, S, Molano, D, Rojas, A, Guerra, K, Villamagua, B, Salgado-Yepez, E, Morocho, D, Remache-Vargas, N, Namendys-Silva, S, Rodriguez, D, Dominguez, G, Barraza, G, Bermudez-Aceves, E, Sanchez-Hurtado, L, Baltazar-Torres, J, Quispe Sierra, R, Chavez, C, von Osten, I, Van Haren, C, Smalley, N, Kol, M, Wong, H, Smith, R, Yu, L, Wu, X, Chao, L, Zhai, Q, Wu, D, Zhang, X, Jing, X, Bigornia, R, Ikeda-Maquiling, Y, Robles, J, Palo, J, Nguyen, T, Dao, C, Dixit, S, Gurjar, M, Reddy, P, Pravin, A, Simran, S, Ramakrishnan, N, Shetty, R, Udwadia, F, Faraz, M, Indraratna, K, Rajasinhe, J, Auer J., Schatzl G., Mach K., Gruber H., Schreurs E., Vander Laenen M., Ceunen H., Wauters J., Francois G., Deschamps P., Castanares D., Debels D., Pierrakos C., Vincent J. L., Taccone F., Vymazal T., Gornik I., Vujiaklija Brajkovic A., Medici R., Nielsen J., Bendtsen A., Siegel H., Suonsyrja T., Hraech S., Chiche J. -D., Daviaux F., Guillot M., Castelain V., Losser R. -R., Novy E., Timsit J. -F., Bouadma L., Misset B., Philippart F., Mallat J., Zogheib E., Miclo M., Teboul J. -L., Anguel N., Darmon M., Pham T., Barberet G., Plantefeve G., Floccard B., Kheladze Z., Reinhart K., Sakr Y., Bloos F., Faltlhauser A., Helmes T., Zacharowski K., Meybohm P., Schwarzkopf K., Christ M., Baumgaertel M., John S., Nentwich J., Deja M., Goldmann A., Gottschalk A., Honig F., Siepe B., Goebel U., Lehmke J., Behrens S., Fiedler K., Sagoschen I., Riessen R., Haap M., Simon P., Kaisers U., Niesen M., Jaschinski U., Hoersch S., Jung A., Allgaeuer S., Haake H., Lange A., Papanikolaou M., Balla M., Giannakou M., Soultati I., Nikos G., Koulouras V., Kyriazopoulos G., Gkika D., Vlachogianni G., Psaroulis K., Mouloudi E., Massa E., Nichol A., Meany E., Motherway C., Bellani G., Pota V., Schiavone V., Girardis M., Busani S., Petrucci N., Di Pasquale R., Mazzini P., Molin A., Pellerano G., Volta C., Spadaro S., Guarracino F., Savioli M., Pellis T., Chinellato N., Gatta A., Cecchini F., Raineri S. M., Cortegiani A., Kekstas G., Karosas V., Anguseva T., Mitrev Z., Beck O., Cimic N., Janssen G., Bormans L., Kuiper M., Koopmans K., Den Boer S., de Groot M., Dennesen P., van den Bosch J., Kluge G., Mikaszewska-Sokolewicz M., Lazowski T., Chruscikowski M., Machon J., Adamik B., Kubler A., Wieczorek A., Afonso S., Matos R., Catorze N., Araujo A., Costa Z., Pais-de-Lacerda A., Martins I., Cardiga R., Fernandes L., Serra I., Martinho A., Tomescu D., Popescu M., Scarlatescu E., Stoica R., Macri A., Filipescu D., Rupnik E., Tomic V., Sifrer F., Sole Violan J., Ferrer Aguero J. M., Izura B. J., Monedero P., Munos de Cabo C., Aguilar G., Belda F. J., Blanquer J., Nives Carbonell E., Lopez-Delgado J. -C., Aragon C., Joya C., Ortiz-Leyba C., Fernandez Gonzalez C. J., de la Torre-Prados M. -V., Puerto-Morlan A., Araujo Aguilar P., Tomas Marsilla J. I., Vera Aratcoz P., Olmo A., Ferrer Roca R., Catalan R. M., Garcia Olivares P., Albis A., Alvarez M., Corcoles Gonzalez V., Gutierrez Rubio J. M., Montoiro Allue R., Rubio Mateo-Sidron J., Hobrok M., Cecconi M., Di Tomasso N., Raj A., Szakmany T., Srinivasa L., Mathew S., Ferguson A., Blahut-Zugaj M., Watters M., Henderson S., Sim M., Csabi P., O'Neill O., Nutt C., Humphreys S., Bhowmick K., Donnelly A., O'Kane S., Garfield M., Jha R., Unni N., Gordon A., Rubulotta F., Ravi K., Lunch G., Franco F., Higgs D., Strandvik G., Jonas A., Hopkins P., Hurst T., Bellini A., Balogun O., Srinivasan R., Ostermann M., Alexander P., McCalman K., Bedford J., Fulop M., Brescia G., Strachan J., Meyer J., Stotz M., Brett S., Zand F., Nikandish R., Hashemian S., Jamaati H., Alsheikhly A. S., Almekhlafi G., Albarrak M., Maghrabi A., Salahuddin N., Aisa T., Atalan H. K., Sungur M., Hegazi M., Bauer P., Mukkera S., Fried J., Barger M., Gueret R., Gonzalez C., Lovesio C., Dellera C., Barrios D., Leite Mendes C., Gottardo P., Caser E., Santos C., Carvalho A., Teixeira C., Samaniego W., Whittle S., Molano D., Rojas A., Guerra K., Villamagua B., Salgado-Yepez E., Morocho D., Remache-Vargas N., Namendys-Silva S., Rodriguez D., Dominguez G., Barraza G., Bermudez-Aceves E., Sanchez-Hurtado L. A., Baltazar-Torres J. A., Quispe Sierra R., Chavez C., von Osten I., Van Haren C., Smalley N., Kol M., Wong H., Smith R., Yu L., Wu X., Chao L., Zhai Q., Wu D., Zhang X., Jing X., Bigornia R., Ikeda-Maquiling Y., Robles J., Palo J. E., Nguyen T., Dao C., Dixit S., Gurjar M., Reddy P., Pravin A., Simran S., Ramakrishnan N., Shetty R., Udwadia F., Faraz M., Indraratna K., Rajasinhe J., Auer J., Auer, J, Schatzl, G, Mach, K, Gruber, H, Schreurs, E, Vander Laenen, M, Ceunen, H, Wauters, J, Francois, G, Deschamps, P, Castanares, D, Debels, D, Pierrakos, C, Vincent, J, Taccone, F, Vymazal, T, Gornik, I, Vujiaklija Brajkovic, A, Medici, R, Nielsen, J, Bendtsen, A, Siegel, H, Suonsyrja, T, Hraech, S, Chiche, J, Daviaux, F, Guillot, M, Castelain, V, Losser, R, Novy, E, Timsit, J, Bouadma, L, Misset, B, Philippart, F, Mallat, J, Zogheib, E, Miclo, M, Teboul, J, Anguel, N, Darmon, M, Pham, T, Barberet, G, Plantefeve, G, Floccard, B, Kheladze, Z, Reinhart, K, Sakr, Y, Bloos, F, Faltlhauser, A, Helmes, T, Zacharowski, K, Meybohm, P, Schwarzkopf, K, Christ, M, Baumgaertel, M, John, S, Nentwich, J, Deja, M, Goldmann, A, Gottschalk, A, Honig, F, Siepe, B, Goebel, U, Lehmke, J, Behrens, S, Fiedler, K, Sagoschen, I, Riessen, R, Haap, M, Simon, P, Kaisers, U, Niesen, M, Jaschinski, U, Hoersch, S, Jung, A, Allgaeuer, S, Haake, H, Lange, A, Papanikolaou, M, Balla, M, Giannakou, M, Soultati, I, Nikos, G, Koulouras, V, Kyriazopoulos, G, Gkika, D, Vlachogianni, G, Psaroulis, K, Mouloudi, E, Massa, E, Nichol, A, Meany, E, Motherway, C, Bellani, G, Pota, V, Schiavone, V, Girardis, M, Busani, S, Petrucci, N, Di Pasquale, R, Mazzini, P, Molin, A, Pellerano, G, Volta, C, Spadaro, S, Guarracino, F, Savioli, M, Pellis, T, Chinellato, N, Gatta, A, Cecchini, F, Raineri, S, Cortegiani, A, Kekstas, G, Karosas, V, Anguseva, T, Mitrev, Z, Beck, O, Cimic, N, Janssen, G, Bormans, L, Kuiper, M, Koopmans, K, Den Boer, S, de Groot, M, Dennesen, P, van den Bosch, J, Kluge, G, Mikaszewska-Sokolewicz, M, Lazowski, T, Chruscikowski, M, Machon, J, Adamik, B, Kubler, A, Wieczorek, A, Afonso, S, Matos, R, Catorze, N, Araujo, A, Costa, Z, Pais-de-Lacerda, A, Martins, I, Cardiga, R, Fernandes, L, Serra, I, Martinho, A, Tomescu, D, Popescu, M, Scarlatescu, E, Stoica, R, Macri, A, Filipescu, D, Rupnik, E, Tomic, V, Sifrer, F, Sole Violan, J, Ferrer Aguero, J, Izura, B, Monedero, P, Munos de Cabo, C, Aguilar, G, Belda, F, Blanquer, J, Nives Carbonell, E, Lopez-Delgado, J, Aragon, C, Joya, C, Ortiz-Leyba, C, Fernandez Gonzalez, C, de la Torre-Prados, M, Puerto-Morlan, A, Araujo Aguilar, P, Tomas Marsilla, J, Vera Aratcoz, P, Olmo, A, Ferrer Roca, R, Catalan, R, Garcia Olivares, P, Albis, A, Alvarez, M, Corcoles Gonzalez, V, Gutierrez Rubio, J, Montoiro Allue, R, Rubio Mateo-Sidron, J, Hobrok, M, Cecconi, M, Di Tomasso, N, Raj, A, Szakmany, T, Srinivasa, L, Mathew, S, Ferguson, A, Blahut-Zugaj, M, Watters, M, Henderson, S, Sim, M, Csabi, P, O'Neill, O, Nutt, C, Humphreys, S, Bhowmick, K, Donnelly, A, O'Kane, S, Garfield, M, Jha, R, Unni, N, Gordon, A, Rubulotta, F, Ravi, K, Lunch, G, Franco, F, Higgs, D, Strandvik, G, Jonas, A, Hopkins, P, Hurst, T, Bellini, A, Balogun, O, Srinivasan, R, Ostermann, M, Alexander, P, Mccalman, K, Bedford, J, Fulop, M, Brescia, G, Strachan, J, Meyer, J, Stotz, M, Brett, S, Zand, F, Nikandish, R, Hashemian, S, Jamaati, H, Alsheikhly, A, Almekhlafi, G, Albarrak, M, Maghrabi, A, Salahuddin, N, Aisa, T, Atalan, H, Sungur, M, Hegazi, M, Bauer, P, Mukkera, S, Fried, J, Barger, M, Gueret, R, Gonzalez, C, Lovesio, C, Dellera, C, Barrios, D, Leite Mendes, C, Gottardo, P, Caser, E, Santos, C, Carvalho, A, Teixeira, C, Samaniego, W, Whittle, S, Molano, D, Rojas, A, Guerra, K, Villamagua, B, Salgado-Yepez, E, Morocho, D, Remache-Vargas, N, Namendys-Silva, S, Rodriguez, D, Dominguez, G, Barraza, G, Bermudez-Aceves, E, Sanchez-Hurtado, L, Baltazar-Torres, J, Quispe Sierra, R, Chavez, C, von Osten, I, Van Haren, C, Smalley, N, Kol, M, Wong, H, Smith, R, Yu, L, Wu, X, Chao, L, Zhai, Q, Wu, D, Zhang, X, Jing, X, Bigornia, R, Ikeda-Maquiling, Y, Robles, J, Palo, J, Nguyen, T, Dao, C, Dixit, S, Gurjar, M, Reddy, P, Pravin, A, Simran, S, Ramakrishnan, N, Shetty, R, Udwadia, F, Faraz, M, Indraratna, K, Rajasinhe, J, Auer J., Schatzl G., Mach K., Gruber H., Schreurs E., Vander Laenen M., Ceunen H., Wauters J., Francois G., Deschamps P., Castanares D., Debels D., Pierrakos C., Vincent J. L., Taccone F., Vymazal T., Gornik I., Vujiaklija Brajkovic A., Medici R., Nielsen J., Bendtsen A., Siegel H., Suonsyrja T., Hraech S., Chiche J. -D., Daviaux F., Guillot M., Castelain V., Losser R. -R., Novy E., Timsit J. -F., Bouadma L., Misset B., Philippart F., Mallat J., Zogheib E., Miclo M., Teboul J. -L., Anguel N., Darmon M., Pham T., Barberet G., Plantefeve G., Floccard B., Kheladze Z., Reinhart K., Sakr Y., Bloos F., Faltlhauser A., Helmes T., Zacharowski K., Meybohm P., Schwarzkopf K., Christ M., Baumgaertel M., John S., Nentwich J., Deja M., Goldmann A., Gottschalk A., Honig F., Siepe B., Goebel U., Lehmke J., Behrens S., Fiedler K., Sagoschen I., Riessen R., Haap M., Simon P., Kaisers U., Niesen M., Jaschinski U., Hoersch S., Jung A., Allgaeuer S., Haake H., Lange A., Papanikolaou M., Balla M., Giannakou M., Soultati I., Nikos G., Koulouras V., Kyriazopoulos G., Gkika D., Vlachogianni G., Psaroulis K., Mouloudi E., Massa E., Nichol A., Meany E., Motherway C., Bellani G., Pota V., Schiavone V., Girardis M., Busani S., Petrucci N., Di Pasquale R., Mazzini P., Molin A., Pellerano G., Volta C., Spadaro S., Guarracino F., Savioli M., Pellis T., Chinellato N., Gatta A., Cecchini F., Raineri S. M., Cortegiani A., Kekstas G., Karosas V., Anguseva T., Mitrev Z., Beck O., Cimic N., Janssen G., Bormans L., Kuiper M., Koopmans K., Den Boer S., de Groot M., Dennesen P., van den Bosch J., Kluge G., Mikaszewska-Sokolewicz M., Lazowski T., Chruscikowski M., Machon J., Adamik B., Kubler A., Wieczorek A., Afonso S., Matos R., Catorze N., Araujo A., Costa Z., Pais-de-Lacerda A., Martins I., Cardiga R., Fernandes L., Serra I., Martinho A., Tomescu D., Popescu M., Scarlatescu E., Stoica R., Macri A., Filipescu D., Rupnik E., Tomic V., Sifrer F., Sole Violan J., Ferrer Aguero J. M., Izura B. J., Monedero P., Munos de Cabo C., Aguilar G., Belda F. J., Blanquer J., Nives Carbonell E., Lopez-Delgado J. -C., Aragon C., Joya C., Ortiz-Leyba C., Fernandez Gonzalez C. J., de la Torre-Prados M. -V., Puerto-Morlan A., Araujo Aguilar P., Tomas Marsilla J. I., Vera Aratcoz P., Olmo A., Ferrer Roca R., Catalan R. M., Garcia Olivares P., Albis A., Alvarez M., Corcoles Gonzalez V., Gutierrez Rubio J. M., Montoiro Allue R., Rubio Mateo-Sidron J., Hobrok M., Cecconi M., Di Tomasso N., Raj A., Szakmany T., Srinivasa L., Mathew S., Ferguson A., Blahut-Zugaj M., Watters M., Henderson S., Sim M., Csabi P., O'Neill O., Nutt C., Humphreys S., Bhowmick K., Donnelly A., O'Kane S., Garfield M., Jha R., Unni N., Gordon A., Rubulotta F., Ravi K., Lunch G., Franco F., Higgs D., Strandvik G., Jonas A., Hopkins P., Hurst T., Bellini A., Balogun O., Srinivasan R., Ostermann M., Alexander P., McCalman K., Bedford J., Fulop M., Brescia G., Strachan J., Meyer J., Stotz M., Brett S., Zand F., Nikandish R., Hashemian S., Jamaati H., Alsheikhly A. S., Almekhlafi G., Albarrak M., Maghrabi A., Salahuddin N., Aisa T., Atalan H. K., Sungur M., Hegazi M., Bauer P., Mukkera S., Fried J., Barger M., Gueret R., Gonzalez C., Lovesio C., Dellera C., Barrios D., Leite Mendes C., Gottardo P., Caser E., Santos C., Carvalho A., Teixeira C., Samaniego W., Whittle S., Molano D., Rojas A., Guerra K., Villamagua B., Salgado-Yepez E., Morocho D., Remache-Vargas N., Namendys-Silva S., Rodriguez D., Dominguez G., Barraza G., Bermudez-Aceves E., Sanchez-Hurtado L. A., Baltazar-Torres J. A., Quispe Sierra R., Chavez C., von Osten I., Van Haren C., Smalley N., Kol M., Wong H., Smith R., Yu L., Wu X., Chao L., Zhai Q., Wu D., Zhang X., Jing X., Bigornia R., Ikeda-Maquiling Y., Robles J., Palo J. E., Nguyen T., Dao C., Dixit S., Gurjar M., Reddy P., Pravin A., Simran S., Ramakrishnan N., Shetty R., Udwadia F., Faraz M., Indraratna K., and Rajasinhe J.
- Abstract
In both the original publication (DOI 10.1007/s00134-015-4206-2) and the first erratum (DOI 10.1007/s00134-016-4317-4), the members of the IC-GLOSSARI Investigators and the ESICM Trials Group were provided in such a way that they could not be indexed as collaborators on PubMed. The publisher apologizes for these errors and is pleased to list the members of the groups here: (Table presented.).
- Published
- 2018
11. Erratum to: The Intensive Care Global Study on Severe Acute Respiratory Infection (ICâGLOSSARI): a multicenter, multinational, 14-day inception cohort study (Intensive Care Medicine, (2016), 42, 5, (953), 10.1007/s00134-016-4317-4)
- Author
-
Sakr, Yasser, Ferrer, Ricard, Reinhart, Konrad, Beale, Richard, Rhodes, Andrew, Moreno, Rui, Timsit, Jean Francois, Brochard, Laurent, Thompson, B. Taylor, Rezende, Ederlon, Chiche, Jean Daniel, Auer, J., Schatzl, G., Mach, K., Gruber, H., Schreurs, E., Vander Laenen, M., Ceunen, H., Wauters, J., Francois, G., Deschamps, P., Castanares, D., Debels, D., Pierrakos, C., Vincent, J. L., Taccone, F., Vymazal, T., Gornik, I., Vujiaklija Brajkovic, A., Medici, R., Nielsen, J., Bendtsen, A., Siegel, H., Suonsyrjä, T., Hraech, S., Daviaux, F., Guillot, M., Castelain, V., Losser, R. -R., Novy, E., Bouadma, L., Misset, B., Philippart, F., Mallat, J., Zogheib, E., Miclo, M., Teboul, J. -L., Anguel, N., Darmon, M., Pham, T., Barberet, G., Plantefeve, G., Floccard, B., Kheladze, Z., Bloos, F., Faltlhauser, A., Helmes, T., Zacharowski, K., Meybohm, P., Schwarzkopf, K., Christ, M., Baumgaertel, M., John, S., Nentwich, J., Deja, M., Goldmann, A., Gottschalk, A., Honig, F., Siepe, B., Goebel, U., Lehmke, J., Behrens, S., Fiedler, K., Sagoschen, I., Riessen, R., Haap, M., Simon, Ph., Kaisers, U., Niesen, M., Jaschinski, U., Hoersch, S., Jung, A., Allgaeuer, S., Haake, H., Lange, A., Papanikolaou, M., Balla, M., Giannakou, M., Soultati, I., Nikos, G., Koulouras, V., Kyriazopoulos, G., Gkika, D., Vlachogianni, G., Psaroulis, K., Mouloudi, E., Massa, E., Nichol, A., Meany, E., Motherway, C., Bellani, G., Pota, V., Schiavone, V., Girardis, M., Busani, S., Petrucci, N., Di Pasquale, R., Mazzini, P., Molin, A., Pellerano, G., Volta, C., Spadaro, S., Guarracino, F., Savioli, M., Pellis, T., Chinellato, N., Gatta, A., Cecchini, F., Raineri, S. M., Cortegiani, A., Kekstas, G., Karosas, V., Anguseva, T., Mitrev, Z., Beck, O., Cimic, N., Janssen, G., Bormans, L., Kuiper, M., Koopmans, K., Den Boer, S., de Groot, M., Dennesen, P., van den Bosch, J., Kluge, G., Mikaszewska-Sokolewicz, M., Lazowski, T., Chruscikowski, M., Machon, J., Adamik, B., Kübler, A., Wieczorek, A., Afonso, S., Matos, R., Catorze, N., Araujo, A., Costa, Z., Pais-de-Lacerda, A., Martins, I., Cardiga, R., Fernandes, L., Serra, I., Martinho, A., Tomescu, D., Popescu, M., Scarlatescu, E., Stoica, R., Macri, A., Filipescu, D., Rupnik, E., Tomic, V., Sifrer, F., Sole Violan, J., Ferrer Agüero, J. M., Izura, J., Monedero, P., de Cabo, C. Muños, Aguilar, G., Belda, F. J., Blanquer, J., Nives Carbonell, E., Lopez-Delgado, J. -C., Aragon, C., Joya, C., Ortiz-Leyba, C., Fernandez Gonzalez, C. J., de la Torre-Prados, M. -V., Puerto-Morlan, A., Araujo Aguilar, P., Tomás Marsilla, J. I., Vera Aratcoz, P., Olmo, A., Ferrer Roca, R., Catalan, R. M., Garcia Olivares, P., Albis, A., Alvarez, M., Corcoles Gonzalez, V., Gutierrez Rubio, J. M., Montoiro Allue, R., Rubio Mateo-Sidron, J., Hobrok, M., Cecconi, M., Di Tomasso, N., Raj, A., Szakmany, T., Srinivasa, L., Mathew, S., Ferguson, A., Blahut-Zugaj, M., Watters, M., Henderson, S., Sim, M., Csabi, P., O’Neill, O., Nutt, C., Humphreys, S., Bhowmick, K., Donnelly, A., O’Kane, S., Garfield, M., Jha, R., Unni, N., Gordon, A., Rubulotta, F., Ravi, K., Lunch, G., Franco, F., Higgs, D., Strandvik, G., Jonas, A., Hopkins, Ph., Hurst, T., Bellini, A., Balogun, O., Srinivasan, R., Ostermann, M., Alexander, P., McCalman, K., Bedford, J., Fulop, M., Brescia, G., Strachan, J., Meyer, J., Stotz, M., Brett, S., Zand, F., Nikandish, R., Hashemian, S., Jamaati, H., Alsheikhly, A. S., Almekhlafi, G., Albarrak, M., Maghrabi, A., Salahuddin, N., Aisa, T., Atalan, H. K., Sungur, M., Hegazi, M., Bauer, P., Mukkera, S., Fried, J., Barger, M., Gueret, R., Gonzalez, C., Lovesio, C., Dellera, Ch., Barrios, D., Leite Mendes, C., Gottardo, P., Caser, E., Santos, C., Carvalho, A., Teixeira, C., Samaniego, W., Whittle, S., Molano, D., Rojas, A., Guerra, K., Villamagua, B., Salgado-Yepez, E., Morocho, D., Remache-Vargas, N., Ñamendys-Silva, S., Rodriguez, D., Dominguez, G., Barraza, G., Bermudez-Aceves, E., Sanchez-Hurtado, L. A., Baltazar-Torres, J. A., Quispe Sierra, R., Chavez, C., von Osten, I., Van Haren, C., Smalley, N., Kol, M., Wong, H., Smith, R., Yu, L., Wu, X., Chao, L., Zhai, Q., Wu, D., Zhang, X., Jing, X., Bigornia, R., Ikeda-Maquiling, Y., Robles, J., Palo, J. E., Nguyen, T., Dao, C., Dixit, S., Gurjar, M., Reddy, P., Pravin, A., Simran, S., Ramakrishnan, N., Shetty, R., Udwadia, F., Faraz, M., Indraratna, K., Rajasinhe, J., Sakr, Yasser, Ferrer, Ricard, Reinhart, Konrad, Beale, Richard, Rhodes, Andrew, Moreno, Rui, Timsit, Jean Francoi, Brochard, Laurent, Thompson, B. Taylor, Rezende, Ederlon, Chiche, Jean Daniel, Auer, J., Schatzl, G., Mach, K., Gruber, H., Schreurs, E., Vander Laenen, M., Ceunen, H., Wauters, J., Francois, G., Deschamps, P., Castanares, D., Debels, D., Pierrakos, C., Vincent, J.L., Taccone, F., Vymazal, T., Gornik, I., Vujiaklija Brajkovic, A., Medici, R., Nielsen, J., Bendtsen, A., Siegel, H., Suonsyrjä, T., Hraech, S., Daviaux, F., Guillot, M., Castelain, V., Losser, R.-R., Novy, E., Bouadma, L., Misset, B., Philippart, F., Mallat, J., Zogheib, E., Miclo, M., Teboul, J.-L., Anguel, N., Darmon, M., Pham, T., Barberet, G., Plantefeve, G., Floccard, B., Kheladze, Z., Bloos, F., Faltlhauser, A., Helmes, T., Zacharowski, K., Meybohm, P., Schwarzkopf, K., Christ, M., Baumgaertel, M., John, S., Nentwich, J., Deja, M., Goldmann, A., Gottschalk, A., Honig, F., Siepe, B., Goebel, U., Lehmke, J., Behrens, S., Fiedler, K., Sagoschen, I., Riessen, R., Haap, M., Simon, Ph., Kaisers, U., Niesen, M., Jaschinski, U., Hoersch, S., Jung, A., Allgaeuer, S., Haake, H., Lange, A., Papanikolaou, M., Balla, M., Giannakou, M., Soultati, I., Nikos, G., Koulouras, V., Kyriazopoulos, G., Gkika, D., Vlachogianni, G., Psaroulis, K., Mouloudi, E., Massa, E., Nichol, A., Meany, E., Motherway, C., Bellani, G., Pota, V., Schiavone, V., Girardis, M., Busani, S., Petrucci, N., Di Pasquale, R., Mazzini, P., Molin, A., Pellerano, G., Volta, C., Spadaro, S., Guarracino, F., Savioli, M., Pellis, T., Chinellato, N., Gatta, A., Cecchini, F., Raineri, S.M., Cortegiani, A., Kekstas, G., Karosas, V., Anguseva, T., Mitrev, Z., Beck, O., Cimic, N., Janssen, G., Bormans, L., Kuiper, M., Koopmans, K., Den Boer, S., de Groot, M., Dennesen, P., van den Bosch, J., Kluge, G., Mikaszewska-Sokolewicz, M., Lazowski, T., Chruscikowski, M., Machon, J., Adamik, B., Kübler, A., Wieczorek, A., Afonso, S., Matos, R., Catorze, N., Araujo, A., Costa, Z., Pais-de-Lacerda, A., Martins, I., Cardiga, R., Fernandes, L., Serra, I., Martinho, A., Tomescu, D., Popescu, M., Scarlatescu, E., Stoica, R., Macri, A., Filipescu, D., Rupnik, E., Tomic, V., Sifrer, F., Sole Violan, J., Ferrer Agüero, J.M., Izura, J., Monedero, P., de Cabo, C. Muño, Aguilar, G., Belda, F.J., Blanquer, J., Nives Carbonell, E., Lopez-Delgado, J.-C., Aragon, C., Joya, C., Ortiz-Leyba, C., Fernandez Gonzalez, C.J., de la Torre-Prados, M.-V., Puerto-Morlan, A., Araujo Aguilar, P., Tomás Marsilla, J.I., Vera Aratcoz, P., Olmo, A., Ferrer Roca, R., Catalan, R.M., Garcia Olivares, P., Albis, A., Alvarez, M., Corcoles Gonzalez, V., Gutierrez Rubio, J.M., Montoiro Allue, R., Rubio Mateo-Sidron, J., Hobrok, M., Cecconi, M., Di Tomasso, N., Raj, A., Szakmany, T., Srinivasa, L., Mathew, S., Ferguson, A., Blahut-Zugaj, M., Watters, M., Henderson, S., Sim, M., Csabi, P., O’Neill, O., Nutt, C., Humphreys, S., Bhowmick, K., Donnelly, A., O’Kane, S., Garfield, M., Jha, R., Unni, N., Gordon, A., Rubulotta, F., Ravi, K., Lunch, G., Franco, F., Higgs, D., Strandvik, G., Jonas, A., Hopkins, Ph., Hurst, T., Bellini, A., Balogun, O., Srinivasan, R., Ostermann, M., Alexander, P., McCalman, K., Bedford, J., Fulop, M., Brescia, G., Strachan, J., Meyer, J., Stotz, M., Brett, S., Zand, F., Nikandish, R., Hashemian, S., Jamaati, H., Alsheikhly, A.S., Almekhlafi, G., Albarrak, M., Maghrabi, A., Salahuddin, N., Aisa, T., Atalan, H.K., Sungur, M., Hegazi, M., Bauer, P., Mukkera, S., Fried, J., Barger, M., Gueret, R., Gonzalez, C., Lovesio, C., Dellera, Ch., Barrios, D., Leite Mendes, C., Gottardo, P., Caser, E., Santos, C., Carvalho, A., Teixeira, C., Samaniego, W., Whittle, S., Molano, D., Rojas, A., Guerra, K., Villamagua, B., Salgado-Yepez, E., Morocho, D., Remache-Vargas, N., Ñamendys-Silva, S., Rodriguez, D., Dominguez, G., Barraza, G., Bermudez-Aceves, E., Sanchez-Hurtado, L.A., Baltazar-Torres, J.A., Quispe Sierra, R., Chavez, C., von Osten, I., Van Haren, C., Smalley, N., Kol, M., Wong, H., Smith, R., Yu, L., Wu, X., Chao, L., Zhai, Q., Wu, D., Zhang, X., Jing, X., Bigornia, R., Ikeda-Maquiling, Y., Robles, J., Palo, J.E., Nguyen, T., Dao, C., Dixit, S., Gurjar, M., Reddy, P., Pravin, A., Simran, S., Ramakrishnan, N., Shetty, R., Udwadia, F., Faraz, M., Indraratna, K., and Rajasinhe, J.
- Subjects
Critical Care and Intensive Care Medicine - Abstract
In both the original publication (DOI 10.1007/s00134-015-4206-2) and the first erratum (DOI 10.1007/s00134-016-4317-4), the members of the IC-GLOSSARI Investigators and the ESICM Trials Group were provided in such a way that they could not be indexed as collaborators on PubMed. The publisher apologizes for these errors and is pleased to list the members of the groups here: (Table presented.).
- Published
- 2018
12. Improving Students’ Creative Thinking Skills by Combining Cooperative Script and Reciprocal Teaching Models
- Author
-
Ali Usman, Novy Eurika, Ika Priantari, Ahmad Rusdy Awalludin, and Gumilang Mutiara Hilia
- Subjects
cooperative script, reciprocal teaching, cooperative learning, creative thinking ,Education - Abstract
This study aims to describe the increase in students' creative thinking by combining cooperative script learning models with reciprocal teaching. This research is a Class Action Research (CAR). This research was conducted in class XI SMA. Learning tools, essay questions combined with creative thinking, observation sheets of learning implementation, and creative thinking instruments were used to collect data. Data analysis on the increase in creative thinking was calculated using the score gain (N-Gain) formula. The results show an increase in students' creative thinking, namely from cycle I with a score of 0.28 which is included in the low category, rising to a score of 0.5 in cycle II which is included in the medium category. The results of this study indicate an increase in students' learning activities and creative thinking in each learning cycle. Combining cooperative and reciprocal learning models can encourage students to dare to express opinions, thoughts, and ideas to empower students' creative thinking skills. This shows that applying the cooperative learning model, a combination of collaborative learning models with a reciprocal teaching model used continuously, can increase students' learning activities and creative thinking to train them to become self-regulation learners.
- Published
- 2023
- Full Text
- View/download PDF
13. Application de programmes de bon usage des antibiotiques dans les services de réanimation français en 2018 : enquête nationale multicentrique
- Author
-
Delannoy, M., primary, Agrinier, N., additional, Charmillon, A., additional, Dellamonica, J., additional, Degand, N., additional, Leone, M., additional, Pulcini, C., additional, and Novy, E., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Implementation of antibiotic stewardship programmes in French ICUs in 2018: a nationwide cross-sectional survey
- Author
-
Delannoy, M, primary, Agrinier, N, additional, Charmillon, A, additional, Degand, N, additional, Dellamonica, J, additional, Leone, M, additional, Pulcini, C, additional, and Novy, E, additional
- Published
- 2019
- Full Text
- View/download PDF
15. BPCO au stade d’insuffisance respiratoire chronique admis en réanimation et soins intensifs : pronostic et mortalité
- Author
-
Faure, M., primary, Arnout, C., additional, Lemarie, J., additional, Luc, A., additional, Chabot, F., additional, and Novy, E., additional
- Published
- 2018
- Full Text
- View/download PDF
16. Les lésions traumatiques de l’aorte descendante en dehors de l’isthme : particularités diagnostiques et thérapeutiques
- Author
-
Novy, E., Charpentier, C., Guerci, P., Settembre, N., Malikov, S., and Audibert, G.
- Published
- 2013
- Full Text
- View/download PDF
17. Cisaillements accidentels de cathéters périnerveux lors de poses échoguidées
- Author
-
Guerci, P., Novy, E., Guibert, J., Vial, F., Malinovsky, J.-M., and Bouaziz, H.
- Published
- 2013
- Full Text
- View/download PDF
18. Choc hémorragique : aspects physiopathologiques et prise en charge hémodynamique
- Author
-
Novy, E., primary and Levy, B., additional
- Published
- 2014
- Full Text
- View/download PDF
19. Machine learning using the Extreme Gradient Boosting (XGBoost) algorithm predicts 5-day delta of SOFA score at ICU admission in COVID-19 patients
- Author
-
Marie M. Jeitziner, Iris Drvaric, Jan Wiegand, Abele Donati, Janina Apolo, Emanuele Rezoagli, Jesús Escós-Orta, Herminia Lozano-Gómez, Mirko Brenni, Giovanni Camen, Frank Hillgaertner, Sara Moccia, Antje Heise, Alexander Dullenkopf, Michael Stephan, Can Ince, Marcus Laube, Julien Marrel, Michele Bernardini, Barbara Lienhardt-Nobbe, Hernán Aguirre-Bermeo, Alberto Fogagnolo, Dorothea M. Heuberger, Severin Urech, Reto A. Schuepbach, Andrea Glotta, Samuele Ceruti, Isabelle Fleisch, Marc P. Michot, Alice Nova, Matthias P. Hilty, Tomislav Gaspert, Gianfilippo Gangitano, Savino Spadaro, Ivan Chau, Daniele Berardini, Tiziana Perin, Andrea Westphalen, Marie-Reine Losser, Hatem Ksouri, Marie-Hélène Perez, Theodoros Aslanidis, Christoph Haberthuer, Gerardo Vizmanos-Lamotte, Jorge Gámez-Zapata, Filippo Boroli, Adriana Lambert, Serge Grazioli, Petra Salomon, Christian Bürkle, Didier Naon, Philipp Bühler, Dawid L. Staudacher, Miodrag Filipovic, Hermann Redecker, Mario Alfaro-Farias, Massimo Antonelli, Rolf Ensner, Jerome Lavanchy, Lukas Merki, Roberto Ceriani, Anette Ristic, Chiara Cogliati, Reto Andreas Schüpbach, Daniela Selz, Begoña Zalba-Etayo, Anne-Sylvie Ramelet, Thierry Fumeaux, Andrea Carsetti, Peter Gerecke, Riccardo Colombo, Marilene Franchitti Laurent, Fabrizio Turrini, Tobias Wengenmayer, Tobias Welte, Philippe Guerci, Antonella Potalivo, Lucia Migliorelli, Barna Babik, Reza Nikandish, Pedro D. Wendel Garcia, Alberto Martínez, Maria Sole Simonini, Diederik Gommers, Xiana Taboada-Fraga, Jerome Pugin, Peter C. Rimensberger, Angela Algaba-Calderon, FriederikeMeyer zu Bentrup, Agios Pavlos, Thomas Tschoellitsch, Marianne Sieber, Karim Shaikh, Nuria Zellweger, Silvio Brugger, Geoffrey Jurkolow, Anja Baltussen Weber, Maria C. Martín-Delgado, Anita Korsós, Gian-Reto Kleger, Alexander Klarer, Emmanuel Novy, Diego Franch-Llasat, Adrian Tellez, Peter Schott, Jonathan Rilinger, Andreas Christ, Bernd Yuen, Jean-Christophe Laurent, Nadine Gehring, Pedro Castro, Sascha David, Francesca Facondini, Arantxa Lander-Azcona, Maria Grazia Bocci, Maddalena Alessandra Wu, Mallory Moret-Bochatay, Sara Cereghetti, Urs Pietsch, Martina Murrone, Gauthier Delahaye, Luca Romeo, Pascal Locher, Pedro David Wendel Garcia, Michael Sepulcri, Marija Jovic, Katharina Marquardt, Emanuele Frontoni, Patricia Fodor, Emanuele Catena, Tobias Hübner, Thomas Neff, Roger F. Lussman, Matteo Giacomini, Govind Oliver Sridharan, Beatrice Jenni-Moser, Jan Brem, Michael Studhalter, Elif Colak, Raquel Rodríguez-García, Silvia Fabbri, Jens Meier, Lina Petersen, Jonathan Montomoli, Ferran Roche-Campo, Klaus Stahl, Montomoli, J, Romeo, L, Moccia, S, Bernardini, M, Migliorelli, L, Berardini, D, Donati, A, Carsetti, A, Bocci, M, Wendel Garcia, P, Fumeaux, T, Guerci, P, Schupbach, R, Ince, C, Frontoni, E, Hilty, M, Alfaro-Farias, M, Vizmanos-Lamotte, G, Tschoellitsch, T, Meier, J, Aguirre-Bermeo, H, Apolo, J, Martinez, A, Jurkolow, G, Delahaye, G, Novy, E, Losser, M, Wengenmayer, T, Rilinger, J, Staudacher, D, David, S, Welte, T, Stahl, K, Pavlos, A, Aslanidis, T, Korsos, A, Babik, B, Nikandish, R, Rezoagli, E, Giacomini, M, Nova, A, Fogagnolo, A, Spadaro, S, Ceriani, R, Murrone, M, Wu, M, Cogliati, C, Colombo, R, Catena, E, Turrini, F, Simonini, M, Fabbri, S, Potalivo, A, Facondini, F, Gangitano, G, Perin, T, Grazia Bocci, M, Antonelli, M, Gommers, D, Rodriguez-Garcia, R, Gamez-Zapata, J, Taboada-Fraga, X, Castro, P, Tellez, A, Lander-Azcona, A, Escos-Orta, J, Martin-Delgado, M, Algaba-Calderon, A, Franch-Llasat, D, Roche-Campo, F, Lozano-Gomez, H, Zalba-Etayo, B, Michot, M, Klarer, A, Ensner, R, Schott, P, Urech, S, Zellweger, N, Merki, L, Lambert, A, Laube, M, Jeitziner, M, Jenni-Moser, B, Wiegand, J, Yuen, B, Lienhardt-Nobbe, B, Westphalen, A, Salomon, P, Drvaric, I, Hillgaertner, F, Sieber, M, Dullenkopf, A, Petersen, L, Chau, I, Ksouri, H, Sridharan, G, Cereghetti, S, Boroli, F, Pugin, J, Grazioli, S, Rimensberger, P, Burkle, C, Marrel, J, Brenni, M, Fleisch, I, Lavanchy, J, Perez, M, Ramelet, A, Weber, A, Gerecke, P, Christ, A, Ceruti, S, Glotta, A, Marquardt, K, Shaikh, K, Hubner, T, Neff, T, Redecker, H, Moret-Bochatay, M, Bentrup, F, Studhalter, M, Stephan, M, Brem, J, Gehring, N, Selz, D, Naon, D, Kleger, G, Pietsch, U, Filipovic, M, Ristic, A, Sepulcri, M, Heise, A, Franchitti Laurent, M, Laurent, J, Schuepbach, R, Heuberger, D, Buhler, P, Brugger, S, Fodor, P, Locher, P, Camen, G, Gaspert, T, Jovic, M, Haberthuer, C, Lussman, R, Colak, E, Biomedical Engineering and Physics, ACS - Microcirculation, Translational Physiology, ACS - Atherosclerosis & ischemic syndromes, Graduate School, AII - Infectious diseases, and University of Zurich
- Subjects
610 Medicine & health ,Organ dysfunction score ,Machine learning ,computer.software_genre ,Logistic regression ,Clinical decision support system ,law.invention ,law ,Medicine ,Clinical decision support system (CDSS) ,Receiver operating characteristic ,RC86-88.9 ,business.industry ,Clinical decision support systems ,COVID-19 ,Medical emergencies. Critical care. Intensive care. First aid ,Extreme Gradient Boosting (XGBoost) ,Intensive care unit ,Multiple organ failure ,Cohort ,Population study ,SOFA score ,Original Article ,Artificial intelligence ,10023 Institute of Intensive Care Medicine ,business ,Algorithm ,computer ,Predictive modelling - Abstract
Background : Accurate risk stratification of critically ill patients with coronavirus disease 2019 (COVID-19) is essential for optimizing resource allocation, delivering targeted interventions, and maximizing patient survival probability. Machine learning (ML) techniques are attracting increased interest for the development of prediction models as they excel in the analysis of complex signals in data-rich environments such as critical care. Methods : We retrieved data on patients with COVID-19 admitted to an intensive care unit (ICU) between March and October 2020 from the RIsk Stratification in COVID-19 patients in the Intensive Care Unit (RISC-19-ICU) registry. We applied the Extreme Gradient Boosting (XGBoost) algorithm to the data to predict as a binary outcome the increase or decrease in patients’ Sequential Organ Failure Assessment (SOFA) score on day 5 after ICU admission. The model was iteratively cross-validated in different subsets of the study cohort. Results : The final study population consisted of 675 patients. The XGBoost model correctly predicted a decrease in SOFA score in 320/385 (83%) critically ill COVID-19 patients, and an increase in the score in 210/290 (72%) patients. The area under the mean receiver operating characteristic curve for XGBoost was significantly higher than that for the logistic regression model {0.86 vs. 0.69, P
- Published
- 2021
20. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
- Author
-
Rando E, Novy E, Sangiorgi F, De Pascale G, Fantoni M, Murri R, Roberts JA, and Cotta MO
- Subjects
- Humans, Tazobactam pharmacokinetics, Tazobactam therapeutic use, Tazobactam pharmacology, Pneumonia, Bacterial drug therapy, Azabicyclo Compounds pharmacokinetics, Azabicyclo Compounds therapeutic use, Azabicyclo Compounds pharmacology, Carbapenems pharmacokinetics, Carbapenems therapeutic use, Carbapenems pharmacology, Gram-Negative Bacterial Infections drug therapy, Ceftazidime pharmacokinetics, Ceftazidime therapeutic use, Cefiderocol, Meropenem pharmacokinetics, Meropenem therapeutic use, Meropenem pharmacology, Imipenem pharmacokinetics, Imipenem therapeutic use, Drug Resistance, Multiple, Bacterial, Microbial Sensitivity Tests, Cilastatin, Imipenem Drug Combination pharmacokinetics, Cilastatin, Imipenem Drug Combination therapeutic use, Boronic Acids, Heterocyclic Compounds, 1-Ring, beta-Lactamase Inhibitors pharmacokinetics, beta-Lactamase Inhibitors therapeutic use, beta-Lactamase Inhibitors pharmacology, Anti-Bacterial Agents pharmacokinetics, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents pharmacology, Drug Combinations, beta-Lactams pharmacokinetics, beta-Lactams therapeutic use, beta-Lactams pharmacology, Cephalosporins pharmacokinetics, Cephalosporins therapeutic use, Cephalosporins pharmacology, Gram-Negative Bacteria drug effects
- Abstract
Background: Novel beta-lactams show activity against many multidrug-resistant Gram-negative bacteria that cause severe lung infections. Understanding pharmacokinetic/pharmacodynamic characteristics of these agents may help optimise outcomes in the treatment of pneumonia., Objectives: To describe and appraise studies that report pulmonary pharmacokinetic and pharmacodynamic data of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/cilastatin/relebactam and meropenem/vaborbactam., Methods: MEDLINE (PubMed), Embase, Web of Science and Scopus libraries were used for the literature search. Pulmonary population pharmacokinetic and pharmacokinetic/pharmacodynamic studies on adult patients receiving cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/cilastatin/relebactam, and meropenem/vaborbactam published in peer-reviewed journals were included. Two independent authors screened, reviewed and extracted data from included articles. A reporting guideline for clinical pharmacokinetic studies (ClinPK statement) was used for bias assessment. Relevant outcomes were included, such as population pharmacokinetic parameters and probability of target attainment of dosing regimens., Results: Twenty-four articles were included. There was heterogeneity in study methods and reporting of results, with diversity across studies in adhering to the ClinPK statement checklist. Ceftolozane/tazobactam was the most studied agent. Only two studies collected epithelial lining fluid samples from patients with pneumonia. All the other phase I studies enrolled healthy subjects. Significant population heterogeneity was evident among available population pharmacokinetic models. Probabilities of target attainment rates above 90% using current licensed dosing regiments were reported in most studies., Conclusions: Although lung pharmacokinetics was rarely described, this review observed high target attainment using plasma pharmacokinetic data for all novel beta-lactams. Future studies should describe lung pharmacokinetics in patient populations at risk of carbapenem-resistant pathogen infections., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis.
- Author
-
Abdul-Aziz MH, Hammond NE, Brett SJ, Cotta MO, De Waele JJ, Devaux A, Di Tanna GL, Dulhunty JM, Elkady H, Eriksson L, Hasan MS, Khan AB, Lipman J, Liu X, Monti G, Myburgh J, Novy E, Omar S, Rajbhandari D, Roger C, Sjövall F, Zaghi I, Zangrillo A, Delaney A, and Roberts JA
- Subjects
- Adult, Humans, Critical Illness, Drug Administration Schedule, Infusions, Intravenous, Intensive Care Units, Randomized Controlled Trials as Topic, Time Factors, beta Lactam Antibiotics administration & dosage, Sepsis drug therapy, Sepsis mortality, Shock, Septic drug therapy, Shock, Septic mortality
- Abstract
Importance: There is uncertainty about whether prolonged infusions of β-lactam antibiotics improve clinically important outcomes in critically ill adults with sepsis or septic shock., Objective: To determine whether prolonged β-lactam antibiotic infusions are associated with a reduced risk of death in critically ill adults with sepsis or septic shock compared with intermittent infusions., Data Sources: The primary search was conducted with MEDLINE (via PubMed), CINAHL, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov from inception to May 2, 2024., Study Selection: Randomized clinical trials comparing prolonged (continuous or extended) and intermittent infusions of β-lactam antibiotics in critically ill adults with sepsis or septic shock., Data Extraction and Synthesis: Data extraction and risk of bias were assessed independently by 2 reviewers. Certainty of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation approach. A bayesian framework was used as the primary analysis approach and a frequentist framework as the secondary approach., Main Outcomes and Measures: The primary outcome was all-cause 90-day mortality. Secondary outcomes included intensive care unit (ICU) mortality and clinical cure., Results: From 18 eligible randomized clinical trials that included 9108 critically ill adults with sepsis or septic shock (median age, 54 years; IQR, 48-57; 5961 men [65%]), 17 trials (9014 participants) contributed data to the primary outcome. The pooled estimated risk ratio for all-cause 90-day mortality for prolonged infusions of β-lactam antibiotics compared with intermittent infusions was 0.86 (95% credible interval, 0.72-0.98; I2 = 21.5%; high certainty), with a 99.1% posterior probability that prolonged infusions were associated with lower 90-day mortality. Prolonged infusion of β-lactam antibiotics was associated with a reduced risk of intensive care unit mortality (risk ratio, 0.84; 95% credible interval, 0.70-0.97; high certainty) and an increase in clinical cure (risk ratio, 1.16; 95% credible interval, 1.07-1.31; moderate certainty)., Conclusions and Relevance: Among adults in the intensive care unit who had sepsis or septic shock, the use of prolonged β-lactam antibiotic infusions was associated with a reduced risk of 90-day mortality compared with intermittent infusions. The current evidence presents a high degree of certainty for clinicians to consider prolonged infusions as a standard of care in the management of sepsis and septic shock., Trial Registration: PROSPERO Identifier: CRD42023399434.
- Published
- 2024
- Full Text
- View/download PDF
22. Population pharmacokinetics of prophylactic cefoxitin in elective bariatric surgery patients: a prospective monocentric study.
- Author
-
Novy E, Liu X, Hernández-Mitre MP, Belveyre T, Scala-Bertola J, Roberts JA, and Parker SL
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Obesity surgery, Prospective Studies, Surgical Wound Infection prevention & control, Anti-Bacterial Agents pharmacokinetics, Anti-Bacterial Agents administration & dosage, Antibiotic Prophylaxis methods, Bariatric Surgery, Cefoxitin pharmacokinetics, Cefoxitin administration & dosage, Elective Surgical Procedures, Microbial Sensitivity Tests
- Abstract
Background: This study describes the population pharmacokinetics of cefoxitin in obese patients undergoing elective bariatric surgery and evaluates different dosing regimens for achievement of pre-defined target exposures., Methods: Serial blood samples were collected during surgery with relevant clinical data. Total serum cefoxitin concentrations were measured by chromatographic assay and analysed using a population PK approach with Pmetrics®. The cefoxitin unbound fraction (fu) was estimated. Dosing simulations were performed to ascertain the probability of target attainment (PTA) to achieve cefoxitin fu above minimum inhibitory concentrations (MIC) from surgical incision to wound closure. Fractional target attainment (FTA) was calculated against MIC distributions of common pathogens., Results: A total of 123 obese patients (median BMI 44.3 kg/m
2 ) were included with 381 cefoxitin concentration values. Cefoxitin was best described by a one-compartment model, with a mean clearance and volume of distribution of 10.9 ± 6.1 L/h and 23.4 ± 10.5 L, respectively. In surgery <2 h, a 2 and a 4 g doses were sufficient for an MIC up to 4 and 8 mg/L (fu 50%), respectively. In prolonged surgery (2-4 h), only continuous infusion enabled optimal PTA for an MIC up to 16 mg/L. Optimal FTAs were obtained against Staphylococcus aureus and Escherichia Coli only when simulating with 50% cefoxitin protein binding (intermittent regimen) and regardless of the protein binding for the continuous infusion., Conclusion: Intermittent dosing regimens resulted in optimal FTAs against susceptible MIC distributions of S. aureus and E. coli when simulating with 50% cefoxitin protein binding. Continuous infusion of cefoxitin may improve FTA regardless of protein binding., Study Registration: Registration on ClinicalTrials.gov, NCT03306290., (Copyright © 2024 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
23. In vitro stability study of 10 beta-lactam antibiotics in human plasma samples.
- Author
-
Brenkman M, Cartau T, Pape E, Kolodziej A, Charmillon A, Novy E, Jouzeau JY, Gambier N, and Scala-Bertola J
- Subjects
- Humans, Drug Stability, Time Factors, Anti-Bacterial Agents blood, Anti-Bacterial Agents pharmacokinetics, beta Lactam Antibiotics blood, beta Lactam Antibiotics pharmacokinetics
- Abstract
Background and Objectives: Beta-lactam antibiotics are reported for some of them to be subject to a rapid degradation in infusion solutions and in human blood samples. However, the current data of stability available in blood samples are limited to a few number of beta-lactam antibiotics, and the methodology of the corresponding studies may be discussed. The objective of the present study is to evaluate the stability of 10 beta-lactam antibiotics in human plasma samples., Methods: Stability of amoxicillin, cefazolin, cefepime, cefotaxime, cefoxitin, ceftazidime, ceftriaxone, imipenem, meropenem, and piperacillin was evaluated at low and high concentrations at 20°C, 4°C, -20°C, and -80°C for 1, 7, 60, and 90 days, respectively., Results: Amoxicillin, cefepime, meropenem, and piperacillin were the least stable antibiotics. The maximum durations allowing the stability for all the evaluated beta-lactams at both tested concentrations were estimated at 3 h, 23 h, 10 days, and 35 days at 20°C, 4°C, -20°C, and -80°C, respectively., Conclusion: We recommend to transport antibiotic plasma samples in ice at 4°C and even at -20°C if these samples come from external hospitals. Ideally, plasma samples should be stored at -80°C if possible; if not, the analysis of the samples should be performed as soon as possible in the limit of 10 days after a storage at -20°C., (© 2023 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
24. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
- Author
-
Novy E, Abdul-Aziz MH, Cheng V, Burrows F, Buscher H, Corley A, Diehl A, Gilder E, Levkovich BJ, McGuinness S, Ordonez J, Parke R, Parker S, Pellegrino V, Reynolds C, Rudham S, Wallis SC, Welch SA, Fraser JF, Shekar K, and Roberts JA
- Subjects
- Humans, Anti-Bacterial Agents pharmacokinetics, Body Weight, Critical Illness therapy, Fluconazole pharmacokinetics, Renal Replacement Therapy, Candidiasis drug therapy, Continuous Renal Replacement Therapy, Extracorporeal Membrane Oxygenation
- Abstract
This multicenter study describes the population pharmacokinetics (PK) of fluconazole in critically ill patients receiving concomitant extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) and includes an evaluation of different fluconazole dosing regimens for achievement of target exposure associated with maximal efficacy. Serial blood samples were obtained from critically ill patients on ECMO and CRRT receiving fluconazole. Total fluconazole concentrations were measured in plasma using a validated chromatographic assay. A population PK model was developed and Monte Carlo dosing simulations were performed using Pmetrics in R. The probability of target attainment (PTA) of various dosing regimens to achieve fluconazole area under the curve to minimal inhibitory concentration ratio (AUC
0-24 /MIC) >100 was estimated. Eight critically ill patients receiving concomitant ECMO and CRRT were included. A two-compartment model including total body weight as a covariate on clearance adequately described the data. The mean (±standard deviation, SD) clearance and volume of distribution were 2.87 ± 0.63 L/h and 15.90 ± 13.29 L, respectively. Dosing simulations showed that current guidelines (initial loading dose of 12 mg/kg then 6 mg/kg q24h) achieved >90% of PTA for a MIC up to 1 mg/L. None of the tested dosing regimens achieved 90% of PTA for MIC above 2 mg/L. Current fluconazole dosing regimen guidelines achieved >90% PTA only for Candida species with MIC <1 mg/L and thus should be only used for Candida-documented infections in critically ill patients receiving concomitant ECMO and CRRT. Total body weight should be considered for fluconazole dose., Competing Interests: The authors declare no conflict of interest.- Published
- 2024
- Full Text
- View/download PDF
25. Combination of serum and peritoneal 1.3-beta-D-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study.
- Author
-
Novy E, Rivière J, Nguyen M, Arfeuille G, Louis G, Bouhemad B, Pottecher J, Hecketsweiler S, Germain A, Laithier FX, Losser MR, Debourgogne A, Bernard Y, Rousseau H, Baumann C, Luc A, Birckener J, Machouart MC, and Guerci P
- Subjects
- Humans, Male, Middle Aged, Aged, Female, Prospective Studies, Glucans, Critical Illness therapy, Antifungal Agents therapeutic use, Sensitivity and Specificity, Candidiasis drug therapy, Intraabdominal Infections diagnosis, Peritonitis diagnosis, beta-Glucans analysis
- Abstract
Background: Intra-abdominal candidiasis (IAC) is difficult to predict in critically ill patients with intra-abdominal infection, leading to the overuse of antifungal treatments. Serum and peritoneal 1.3-beta-D-glucan (sBDG and pBDG) have been proposed to confirm or invalidate the diagnosis of IAC, but clinical studies have reported inconsistent results, notably because of heterogeneous populations with a low IAC prevalence. This study aimed to identify a high-risk IAC population and evaluate pBDG and sBDG in diagnosing IAC., Methods: This prospective multicenter noninterventional French study included consecutive critically ill patients undergoing abdominal surgery for abdominal sepsis. The primary objective was to establish the IAC prevalence. The secondary objective was to explore whether sBDG and pBDG could be used to diagnose IAC. Wako
® beta-glucan test (WT, Fujifilm Wako Chemicals Europe, Neuss, Germany) was used for pBDG measurements. WT and Fungitell® beta-D-glucan assay (FA, Associate of Cape Cod, East Falmouth, USA) were used for sBDG measurements., Results: Between 1 January 2020 and 31 December 2022, 199 patients were included. Patients were predominantly male (63%), with a median age of 66 [54-72] years. The IAC prevalence was 44% (87/199). The main IAC type was secondary peritonitis. Septic shock occurred in 63% of cases. After multivariate analysis, a nosocomial origin was associated with more IAC cases (P = 0.0399). The median pBDG level was significantly elevated in IAC (448 [107.5-1578.0] pg/ml) compared to non-IAC patients (133 [16.0-831.0] pg/ml), P = 0.0021. For a pBDG threshold of 45 pg/ml, the negative predictive value in assessing IAC was 82.3%. The median sBDG level with WT (n = 42) at day 1 was higher in IAC (5 [3.0-9.0] pg/ml) than in non-IAC patients (3 [3.0-3.0] pg/ml), P = 0.012. Similarly, median sBDG level with FA (n = 140) at day 1 was higher in IAC (104 [38.0-211.0] pg/ml) than in non-IAC patients (50 [23.0-141.0] pg/ml), P = 0.009. Combining a peritonitis score < 3, sBDG < 3.3 pg/ml (WT) and pBDG < 45 pg/ml (WT) yielded a negative predictive value of 100%., Conclusion: In critically ill patients with intra-abdominal infection requiring surgery, the IAC prevalence was 44%. Combining low sBDG and pBDG with a low peritonitis score effectively excluded IAC and could limit unnecessary antifungal agent exposure., Trial Registration: The study was registered with ClinicalTrials.gov (ID number 03997929, first registered on June 24, 2019)., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
26. Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.
- Author
-
Novy E, Roger C, Roberts JA, and Cotta MO
- Subjects
- Humans, Antifungal Agents therapeutic use, Antifungal Agents pharmacokinetics, Critical Illness therapy, Candidiasis, Invasive drug therapy, Abdominal Cavity, Intraabdominal Infections drug therapy
- Abstract
Intra-abdominal candidiasis (IAC) is one of the most common of invasive candidiasis observed in critically ill patients. It is associated with high mortality, with up to 50% of deaths attributable to delays in source control and/or the introduction of antifungal therapy. Currently, there is no comprehensive guidance on optimising antifungal dosing in the treatment of IAC among the critically ill. However, this form of abdominal sepsis presents specific pharmacokinetic (PK) alterations and pharmacodynamic (PD) challenges that risk suboptimal antifungal exposure at the site of infection in critically ill patients. This review aims to describe the peculiarities of IAC from both PK and PD perspectives, advocating an individualized approach to antifungal dosing. Additionally, all current PK/PD studies relating to IAC are reviewed in terms of strength and limitations, so that core elements for the basis of future research can be provided., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
27. Interest of a metabolic approach using the calScreener™ technology to detect Candida in the peritoneal fluid: A pilot study.
- Author
-
Novy E, Collot M, Chevallier P, Cunat L, and Machouart M
- Subjects
- Pilot Projects, Candida, Ascitic Fluid
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2023
- Full Text
- View/download PDF
28. Reappraisal of intra-abdominal candidiasis: insights from peritoneal fluid analysis.
- Author
-
Novy E, Esposito M, Birckener J, Germain A, Losser MR, Machouart MC, and Guerci P
- Abstract
Background: The understanding of high mortality associated with intra-abdominal candidiasis (IAC) remains limited. While Candida is considered a harmless colonizer in the digestive tract, its role as a true pathogen in IAC is still debated. Evidence regarding Candida virulence in the human peritoneal fluid are lacking. We hypothesized that during IAC, Candida albicans develops virulence factors to survive to new environmental conditions. The objective of this observational exploratory monocentric study is to investigate the influence of peritoneal fluid (PF) on the expression of C. albicans virulence using a multimodal approach., Materials and Methods: A standardized inoculum of a C. albicans (3.10
6 UFC/mL) reference strain (SC5314) was introduced in vitro into various PF samples obtained from critically ill patients with intra-abdominal infection. Ascitic fluids (AFs) and Sabouraud medium (SBD) were used as control groups. Optical microscopy and conventional culture techniques were employed to assess the morphological changes and growth of C. albicans. Reverse transcriptase qPCR was utilized to quantify the expression levels of five virulence genes. The metabolic production of C. albicans was measured using the calScreener™ technology., Results: A total of 26 PF samples from patients with secondary peritonitis were included in the study. Critically ill patients were mostly male (73%) with a median age of 58 years admitted for urgent surgery (78%). Peritonitis was mostly hospital-acquired (81%), including 13 post-operative peritonitis (50%). The infected PF samples predominantly exhibited polymicrobial composition. The findings revealed substantial variability in C. albicans growth and morphological changes in the PF compared to ascitic fluid. Virulence gene expression and metabolic production were dependent on the specific PF sample and the presence of bacterial coinfection., Conclusions: This study provides evidence of C. albicans virulence expression in the peritoneal fluid. The observed variability in virulence expression suggests that it is influenced by the composition of PF and the presence of bacterial coinfection. These findings contribute to a better understanding of the complex dynamics of intra-abdominal candidiasis and advocate for personalized approach for IAC patients. Trial registration https://clinicaltrials.gov/ (NCT05264571; February 22, 2022)., (© 2023. European Society of Intensive Care Medicine and Springer Nature Switzerland AG.)- Published
- 2023
- Full Text
- View/download PDF
29. The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients.
- Author
-
Novy E, Martinière H, and Roger C
- Abstract
Beta-lactams (BL) are the first line agents for the antibiotic management of critically ill patients with sepsis or septic shock. BL are hydrophilic antibiotics particularly subject to unpredictable concentrations in the context of critical illness because of pharmacokinetic (PK) and pharmacodynamics (PD) alterations. Thus, during the last decade, the literature focusing on the interest of BL therapeutic drug monitoring (TDM) in the intensive care unit (ICU) setting has been exponential. Moreover, recent guidelines strongly encourage to optimize BL therapy using a PK/PD approach with TDM. Unfortunately, several barriers exist regarding TDM access and interpretation. Consequently, adherence to routine TDM in ICU remains quite low. Lastly, recent clinical studies failed to demonstrate any improvement in mortality with the use of TDM in ICU patients. This review will first aim at explaining the value and complexity of the TDM process when translating it to critically ill patient bedside management, interpretating the results of clinical studies and discussion of the points which need to be addressed before conducting further TDM studies on clinical outcomes. In a second time, this review will focus on the future aspects of TDM integrating toxicodynamics, model informed precision dosing (MIPD) and "at risk" ICU populations that deserve further investigations to demonstrate positive clinical outcomes.
- Published
- 2023
- Full Text
- View/download PDF
30. Is therapeutic drug monitoring really helpful for managing piperacillin/tazobactam therapy in critically ill patients?
- Author
-
Novy E, François T, Luc A, Pape E, and Scala-Bertola J
- Subjects
- Humans, Piperacillin, Tazobactam Drug Combination therapeutic use, Piperacillin therapeutic use, Anti-Bacterial Agents therapeutic use, Penicillanic Acid therapeutic use, Critical Illness therapy, Drug Monitoring
- Published
- 2022
- Full Text
- View/download PDF
31. Assessment of current practice for β-lactam therapeutic drug monitoring in French ICUs in 2021: a nationwide cross-sectional survey.
- Author
-
Tritscher P, Delannoy M, Agrinier N, Charmillon A, Degand N, Dellamonica J, Roger C, Leone M, Scala-Bertola J, and Novy E
- Subjects
- Adult, Anti-Bacterial Agents pharmacokinetics, Anti-Bacterial Agents therapeutic use, Cross-Sectional Studies, Humans, Intensive Care Units, Drug Monitoring methods, beta-Lactams pharmacokinetics, beta-Lactams therapeutic use
- Abstract
Background: Current guidelines and literature support the use of therapeutic drug monitoring (TDM) to optimize β-lactam treatment in adult ICU patients., Objectives: To describe the current practice of β-lactam monitoring in French ICUs., Methods: A nationwide cross-sectional survey was conducted from February 2021 to July 2021 utilizing an online questionnaire that was sent as an email link to ICU specialists (one questionnaire per ICU)., Results: Overall, 119 of 221 (53.8%) French ICUs participated. Eighty-seven (75%) respondents reported having access to β-lactam TDM, including 52 (59.8%) with on-site access. β-Lactam concentrations were available in 24-48 h and after 48 h for 36 (41.4%) and 26 (29.9%) respondents, respectively. Most respondents (n = 61; 70.1%) reported not knowing whether the β-lactam concentrations in the TDM results were expressed as unbound fractions or total concentrations. The 100% unbound fraction of the β-lactam above the MIC was the most frequent pharmacokinetic and pharmacodynamic target used (n = 62; 73.0%)., Conclusions: Despite the publication of international guidelines, β-lactam TDM is not optimally used in French ICUs. The two major barriers are β-lactam TDM interpretation and the required time for results., (© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
32. When to start vasopressin in septic shock: the strategy we propose.
- Author
-
Guerci P, Belveyre T, Mongardon N, and Novy E
- Subjects
- Humans, Norepinephrine, Vasoconstrictor Agents pharmacology, Vasoconstrictor Agents therapeutic use, Vasopressins therapeutic use, Shock, Septic drug therapy
- Published
- 2022
- Full Text
- View/download PDF
33. Algorithm for rational use of Film Array Pneumonia Panel in bacterial coinfections of critically ill ventilated COVID-19 patients.
- Author
-
Novy E, Goury A, Thivilier C, Guillard T, and Alauzet C
- Subjects
- Algorithms, Coinfection diagnosis, Humans, Pneumonia, Bacterial diagnosis, Pneumonia, Bacterial microbiology, COVID-19 complications, Critical Illness, Molecular Diagnostic Techniques methods, Pneumonia, Bacterial complications, Respiration, Artificial, SARS-CoV-2
- Abstract
The FilmArray Pneumonia Panel has proven to be an effective tool for rapid detection of main respiratory pathogens. However, its rational use needs appropriate knowledge and formation regarding its indication and interpretation. Herein, we provide some advices to help with success of its daily routine use, particularly in critically ill ventilated COVID-19 patients. Clinical Trial registration number: NCT04453540., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Effects of pupillary reflex dilation-guided opioid administration on remifentanil and morphine consumption during laparoscopic surgery: A randomised controlled trial.
- Author
-
Guerci P, Jay G, Arnout C, Herbain D, Baka N, Poirel O, Novy E, Bouaziz H, and Vial F
- Subjects
- Dilatation, Double-Blind Method, Humans, Morphine, Pain, Postoperative diagnosis, Pain, Postoperative prevention & control, Reflex, Pupillary, Remifentanil, Single-Blind Method, Analgesics, Opioid, Laparoscopy
- Abstract
Background: Analysis of pupillary reflex dilation (PRD) assesses the balance of nociception--antinociception. Laparoscopic surgery induces haemodynamic variations that are misleading. During laparoscopy, PRD guidance helps differentiate haemodynamic changes because of excess nociception from secondary changes related to the reflex release of endocrine factors., Objective: The present study evaluated the effect of PRD-guided antinociception on the administration of intra-operative remifentanil and immediate postoperative morphine consumption in patients undergoing elective laparoscopic surgery., Design: The study was a single-blind, randomised controlled trial., Setting: The study took place at two sites at the University Hospital of Nancy from March 2014 to November 2017., Patients: A total of 100 patients who underwent scheduled laparoscopic surgery were included., Interventions: Patients were randomly given remifentanil guided by PRD (PRD-guided) or standard anaesthesia care (control)., Main Outcome Measures: The primary outcome was intra-operative remifentanil consumption. Secondary outcomes included morphine consumption in the immediate postoperative period and the number of intra-operative haemodynamic events., Results: Data from 95 patients were analysed. Intraoperative remifentanil consumption was lower in the PRD-guided group than in the control group: median [IQR], 0.09 [0.07 to 0.11] vs. 0.14 [0.12 to 0.16] μg kg-1 min-1, with a mean difference (95% confidence Interval, CI) of 0.048 (0.035 to 0.060) μg kg-1 min-1; P < 0.0001. Morphine consumption was 0.13 [0.1 to 0.5] vs. 0.15 [0.11 to 0.4] mg kg-1 (P = 0.52) in the PRD-guided and control groups, respectively. The number of hypertensive and tachycardia events was greater in the PRD-guided group than in the control group: Hypertensive events 60.4% vs. 32.6%, relative risk 1.85 (95% CI, 1.24 to 2.84), P = 0.004; tachycardia events 31.6% vs. 4.3%, relative risk 2.09 (95% CI, 1.45 to 2.84), P < 0.001., Conclusions: When PRD is used to differentiate between haemodynamic events arising from noxious stimuli and those events because of other nonsurgical stimuli, then intra-operative remifentanil administration is reduced intra-operatively during laparoscopic surgery but there was no change in postoperative morphine consumption., Trial Registration: Clinicaltrials.gov NCT02116868., (Copyright © 2021 European Society of Anaesthesiology and Intensive Care. Unauthorized reproduction of this article is prohibited.)
- Published
- 2021
- Full Text
- View/download PDF
35. French multicentre observational study on SARS-CoV-2 infections intensive care initial management: the FRENCH CORONA study.
- Author
-
Roger C, Collange O, Mezzarobba M, Abou-Arab O, Teule L, Garnier M, Hoffmann C, Muller L, Lefrant JY, Guinot PG, Novy E, Abraham P, Clavier T, Bourenne J, Besch G, Favier L, Fiani M, Ouattara A, Joannes-Boyau O, Fischer MO, Leone M, Ait Tamlihat Y, Pottecher J, Cordier PY, Aussant P, Moussa MD, Hautin E, Bouex M, Julia JM, Cady J, Danguy Des Déserts M, Mayeur N, Mura T, and Allaouchiche B
- Subjects
- Aged, Cohort Studies, Critical Care, Humans, Intensive Care Units, Middle Aged, Prospective Studies, Respiration, Artificial, COVID-19, SARS-CoV-2
- Abstract
Aim: Describing acute respiratory distress syndrome patterns, therapeutics management, and outcomes of ICU COVID-19 patients and indentifying risk factors of 28-day mortality., Methods: Prospective multicentre, cohort study conducted in 29 French ICUs. Baseline characteristics, comorbidities, adjunctive therapies, ventilatory support at ICU admission and survival data were collected., Results: From March to July 2020, 966 patients were enrolled with a median age of 66 (interquartile range 58-73) years and a median SAPS II of 37 (29-48). During the first 24 h of ICU admission, COVID-19 patients received one of the following respiratory supports: mechanical ventilation for 559 (58%), standard oxygen therapy for 228 (24%) and high-flow nasal cannula (HFNC) for 179 (19%) patients. Overall, 721 (75%) patients were mechanically ventilated during their ICU stay. Prone positioning and neuromuscular blocking agents were used in 494 (51%) and 460 (48%) patients, respectively. Bacterial co-infections and ventilator-associated pneumonia were diagnosed in 79 (3%) and 411 (43%) patients, respectively. The overall 28-day mortality was 18%. Age, pre-existing comorbidities, severity of respiratory failure and the absence of antiviral therapy on admission were identified as independent predictors of 28-day outcome., Conclusion: Severity of hypoxaemia on admission, older age (> 70 years), cardiovascular and renal comorbidities were associated with worse outcome in COVID-19 patients. Antiviral treatment on admission was identified as a protective factor for 28-day mortality. Ascertaining the outcomes of critically ill COVID-19 patients is crucial to optimise hospital and ICU resources and provide the appropriate intensity level of care., (Copyright © 2021 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
36. Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations.
- Author
-
Belveyre T, Scala-Bertola J, Esposito M, Luc A, Lipman J, and Novy E
- Subjects
- Adult, Anti-Bacterial Agents administration & dosage, Antibiotic Prophylaxis methods, Body Mass Index, Cefoxitin administration & dosage, Chromatography, High Pressure Liquid, Cohort Studies, Female, Humans, Male, Metabolic Syndrome epidemiology, Middle Aged, Obesity surgery, Phenotype, Prospective Studies, Sex Factors, Tandem Mass Spectrometry, Anti-Bacterial Agents pharmacokinetics, Bariatric Surgery, Cefoxitin pharmacokinetics, Obesity metabolism
- Abstract
Background and Objectives: A high inter-individual variability in pharmacokinetic parameters in obese patients is observed. The objective of this study was to evaluate the effect of obesity parameters on the pharmacokinetics of cefoxitin administered for antibiotic prophylaxis during bariatric surgery., Methods: This a secondary analysis of a pharmacokinetic study involving 174 obese patients scheduled for bariatric surgery and receiving a 4-g dose of cefoxitin. Blood samples were collected at incision and wound closure. The total plasma concentrations were assessed utilising a validated high-performance liquid chromatography-tandem mass spectrometry method. The pharmacokinetic and pharmacodynamic target was defined as an estimated free concentration of cefoxitin at the time of wound closure >8 mg/L. Specific evaluated obesity parameters were fat body mass, fat body mass/height
2 , lean body mass, lean body mass/height2 , visceral adipose tissue and presence of a metabolic syndrome., Results: A total of 174 patients (median age 47 years) with a majority of women (75.3%) and a median BMI of 44 kg/m2 were analysed. The percentage of patients who met the pharmacokinetic and pharmacodynamic target was 85.1%. In the whole population, a tendency to fail to reach the target was observed with a higher lean mass over height2 [OR = 0.79; 95% CI (0.62-1.01); P = 0.060]. In the female subgroup, higher lean mass over height2 [OR = 0.63; 95% CI (0.41-0.97); P = 0.037] and the presence of a metabolic syndrome [OR = 0.17; 95% CI (0.03-0.83); P = 0.030] were associated with failure to reach the pharmacokinetic and pharmacodynamic target., Conclusion: Obese patients with a higher lean mass and a metabolic syndrome could constitute a subgroup at risk for cefoxitin under-dosage., (© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)- Published
- 2021
- Full Text
- View/download PDF
37. Infection related catheter complications in patients undergoing prone positioning for acute respiratory distress syndrome: an exposed/unexposed study.
- Author
-
Louis G, Belveyre T, Jacquot A, Hochard H, Aissa N, Kimmoun A, Goetz C, Levy B, and Novy E
- Subjects
- Aged, Critical Care, Female, Humans, Incidence, Intensive Care Units, Male, Middle Aged, Prone Position, Respiratory Distress Syndrome therapy, Retrospective Studies, Severity of Illness Index, Catheter-Related Infections etiology, Patient Positioning adverse effects, Respiratory Distress Syndrome complications
- Abstract
Background: Prone positioning (PP) is a standard of care for patients with moderate-severe acute respiratory distress syndrome (ARDS). While adverse events associated with PP are well-documented in the literature, research examining the effect of PP on the risk of infectious complications of intravascular catheters is lacking., Method: All consecutive ARDS patients treated with PP were recruited retrospectively over a two-year period and formed the exposed group. Intensive care unit (ICU) patients during the same period without ARDS for whom PP was not conducted but who had an equivalent disease severity were matched 1:1 to the exposed group based on age, sex, centre, length of ICU stay and SAPS II (unexposed group). Infection-related catheter complications were defined by a composite criterion, including catheter tip colonization or intravascular catheter-related infection., Results: A total of 101 exposed patients were included in the study. Most had direct ARDS (pneumonia). The median [Q1-Q3] PP session number was 2 [1-4]. These patients were matched with 101 unexposed patients. The mortality rates of the exposed and unexposed groups were 31 and 30%, respectively. The incidence of the composite criterion was 14.2/1000 in the exposed group compared with 8.2/1000 days in the control group (p = 0.09). Multivariate analysis identified PP as a factor related to catheter colonization or infection (p = 0.04)., Conclusion: Our data suggest that PP is associated with a higher risk of CVC infectious complications.
- Published
- 2021
- Full Text
- View/download PDF
38. Prognostic factors associated with six month mortality of critically ill elderly patients admitted to the intensive care unit with severe acute cholangitis.
- Author
-
Novy E, Carrara L, Remen T, Chevaux JB, Losser MR, Louis G, and Guerci P
- Subjects
- Aged, 80 and over, Female, Hospital Mortality, Humans, Intensive Care Units, Male, Prognosis, Retrospective Studies, Cholangitis diagnosis, Cholangitis therapy, Critical Illness
- Abstract
Background: Little is known about the outcomes of elderly patients admitted to the intensive care unit (ICU) with severe acute cholangitis (SAC). The objectives were to describe the 6-month mortality in patients with SAC ≥75 years and to identify factors associated with this mortality., Methods: Bi-center retrospective study of critically ill elderly patients with SAC conducted between 2013 and 2017. Demographic and clinical variables of ICU and hospital stays with a 6-month follow-up were analyzed., Results: 85 patients, with a median [Q1-Q3] age of 83 [80-89] years were enrolled of whom 51 (60%) were men. SAC was due to choledocholithiasis in 72 (85%) patients. Median [Q1-Q3] ICU length of stay was 3 [2-6] days. Median [Q1-Q3] admission SAPS II was 50 [42-70]. The ICU and 6-month mortality rates were 18% and 48% respectively. Multivariate analysis showed that malnutrition (OR = 34.5, 95% CI [1.4-817.9]) and a decrease in SOFA score at 48 h (OR by unit 0.7, 95% CI [0.5-0.9]) were associated with higher 6-month mortality., Conclusion: In their decision-making process, ICU physicians and hepato-pancreato-biliary surgeons could use these data to estimate the probability of survival of an elderly patient presenting with SAC and to offer time-limited trials of intensive care., Trial Registration: NCT03831529., (Copyright © 2020 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. Epidemiology and outcome of patients admitted to intensive care after anaphylaxis in France: a retrospective multicentre study.
- Author
-
Guerci P, Tacquard C, Chenard L, Millard D, Soufir L, Malinovsky JM, Garot M, Lalot JM, Besch G, Louis G, Thion LA, Charpentier C, Kimmoun A, Danguy Des Déserts M, Carreira S, Plantefeve G, Novy E, Abraham P, and Mertes PM
- Subjects
- Aged, Anaphylaxis mortality, Epinephrine therapeutic use, Female, France epidemiology, Humans, Intensive Care Units statistics & numerical data, Lactic Acid blood, Male, Middle Aged, Retrospective Studies, Survivors, Treatment Outcome, Vasoconstrictor Agents therapeutic use, Anaphylaxis epidemiology, Anaphylaxis therapy, Critical Care statistics & numerical data
- Abstract
Background: Few data are available on patients who have experienced anaphylaxis and were admitted to ICUs. The purpose of this observational study was to describe the epidemiology and management of these patients., Methods: This was a multicentre retrospective study carried out in 23 French ICUs between 2012 and 2017. All patients who suffered anaphylaxis and were transferred to an ICU were included. Data were collected using an electronic database after approval by an ethics committee., Results: A total of 339 patients were included, and 17 (5%) died secondary to anaphylaxis. The main triggers were drugs (77%), contrast media (11%), and food (7%). Epinephrine was administered before ICU admission in 88% of patients with Grade III anaphylaxis and 100% of patients with Grade IV anaphylaxis. Most patients with Grades III and IV anaphylaxes did not receive the recommended dose of i.v. fluid of 30 ml kg
-1 within the first 4 h of ICU admission. The time to epinephrine administration was not statistically different between survivors and non-survivors, but non-survivors received a higher dose of epinephrine (median: 5 [3-10] vs 3 [2-7] mg; P<0.0001), which suggests that some forms of anaphylactic shock may be resistant to epinephrine. In multivariate analysis, only lactate concentration at ICU admission was a predictor of death (odds ratio: 1.47 [1.15-1.88]; P=0.002)., Conclusions: Lactate concentration at ICU admission appeared to be the most reliable criterion for assessing prognosis. Epinephrine is widely used during anaphylaxis, but the volume of fluid resuscitation was consistently lower than recommended., Clinical Trial Registration: NCT04290507., (Copyright © 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
40. Preliminary therapeutic drug monitoring data of β-lactams in critically ill patients with SARS-CoV-2 infection.
- Author
-
Novy E, Scala-Bertola J, Roger C, and Guerci P
- Subjects
- Aged, Anti-Bacterial Agents adverse effects, Anti-Bacterial Agents blood, Anti-Bacterial Agents pharmacokinetics, COVID-19, Cefepime adverse effects, Cefepime blood, Coinfection prevention & control, Confusion chemically induced, Confusion etiology, Coronavirus Infections complications, Deep Sedation, Delirium chemically induced, Delirium etiology, Drug Monitoring, Female, Humans, Hypnotics and Sedatives therapeutic use, Male, Middle Aged, Pneumonia, Viral complications, Respiration, Artificial adverse effects, SARS-CoV-2, beta-Lactams adverse effects, beta-Lactams blood, beta-Lactams pharmacokinetics, Anti-Bacterial Agents therapeutic use, Antibiotic Prophylaxis adverse effects, Betacoronavirus, Coronavirus Infections therapy, Critical Illness therapy, Cross Infection prevention & control, Pandemics, Pneumonia, Ventilator-Associated prevention & control, Pneumonia, Viral therapy, Sepsis prevention & control, beta-Lactams therapeutic use
- Published
- 2020
- Full Text
- View/download PDF
41. Smartphone to-do list application to improve workflow in an intensive care unit: A superiority quasi-experimental study.
- Author
-
Esposito M, Rocq PL, Novy E, Remen T, Losser MR, and Guerci P
- Subjects
- Adult, Female, Humans, Male, Non-Randomized Controlled Trials as Topic, Pilot Projects, Prospective Studies, Telecommunications instrumentation, Health Personnel statistics & numerical data, Intensive Care Units organization & administration, Intensive Care Units standards, Mobile Applications statistics & numerical data, Smartphone statistics & numerical data, Telecommunications statistics & numerical data, Workflow
- Abstract
Background: Smartphone to-do list app was hypothesized to be more efficient than a paper-based list in the management of workflow and to provide additional benefits., Purpose: To analyze the impact of a mobile task-management application on the workflow of an ICU medical staff., Methods: Superiority by a margin test, quasi-experimental study comparing the use of a smartphone application versus standard practice regarding tasks management in an academic ICU. Superiority margin was set at 8 % based on a pilot study. During two periods of 20 working days each (October 2018 and January 2019), medical staff managed tasks with both methods on a weekly rotation basis. Primary outcome was the proportion of daily tasks completed. Secondary outcomes assessed users' satisfaction and the impact of the app in terms of changes in clinical practice., Results: 25 ICU physicians were enrolled. A total of 1983 tasks were recorded. The proportion of completed tasks per day was higher when using the smartphone app (99 % [96-100] versus 95 % [93-98] for the standard group, p = 0.006), but did not reach the superiority margin. Smartphone application was perceived as positive experience, as participants felt that they forgot fewer tasks (p = 0.02), were more aware of their progress on ongoing or remaining tasks (p = 0.03) and observed an improvement in communication among the medical staff (p = 0.03)., Conclusion: This study failed to demonstrate the superiority of a smartphone app over paper-based lists regarding the proportion of daily tasks completed. However, positive feedback regarding the application was received from the medical staff., Competing Interests: Declaration of Competing Interest None., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
42. Serum and peritoneal exudate concentrations after high doses of β-lactams in critically ill patients with severe intra-abdominal infections: an observational prospective study.
- Author
-
Leon L, Guerci P, Pape E, Thilly N, Luc A, Germain A, Butin-Druoton AL, Losser MR, Birckener J, Scala-Bertola J, and Novy E
- Subjects
- Aged, Critical Illness, Cross Infection complications, Dose-Response Relationship, Drug, Female, France, Humans, Intraabdominal Infections microbiology, Male, Middle Aged, Peritonitis drug therapy, Peritonitis microbiology, Prospective Studies, Ascitic Fluid chemistry, Intraabdominal Infections drug therapy, beta-Lactams blood, beta-Lactams therapeutic use
- Abstract
Background: Critically ill patients with severe intra-abdominal infections (IAIs) requiring surgery may undergo several pharmacokinetic (PK) alterations that can lead to β-lactam underdosage., Objectives: To measure serum and peritoneal exudate concentrations of β-lactams after high doses and optimal administration schemes., Methods: This observational prospective study included critically ill patients with suspicion of IAI who required surgery and a β-lactam antibiotic as empirical therapy. Serum and peritoneal exudate concentrations were measured during surgery and after a 24 h steady-state period. The PK/pharmacodynamic (PD) target was to obtain serum β-lactam concentrations of 100% fT>4×MIC based on a worst-case scenario (based on the EUCAST highest epidemiological cut-off values) before bacterial documentation (a priori) and redefined following determination of the MIC for the isolated bacteria (a posteriori). Registered with ClinicalTrials.gov (NCT03310606)., Results: Forty-eight patients were included with a median (IQR) age of 64 (53-74) years and a SAPS II of 40 (32-65). The main diagnosis was secondary nosocomial peritonitis. Piperacillin/tazobactam was the most administered β-lactam antibiotic (75%). The serum/peritoneal piperacillin/tazobactam ratio was 0.88 (0.64-0.97) after a 24 h steady-state period. Prior to bacterial documentation, 16 patients (33.3%) achieved the a priori PK/PD target. The identification of microorganisms was available for 34 patients (71%). Based on the MIC for isolated bacteria, 78% of the patients achieved the serum PK/PD target., Conclusions: In severe IAIs, high doses of β-lactams ensured 100% fT>4×MIC in the serum for 78% of critically ill patients with severe IAIs within the first 24 h. In order to define optimal β-lactam dosing, the PK/PD target should take into account the tissue penetration and local ecology., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
43. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study.
- Author
-
Guerci P, Bellut H, Mokhtari M, Gaudefroy J, Mongardon N, Charpentier C, Louis G, Tashk P, Dubost C, Ledochowski S, Kimmoun A, Godet T, Pottecher J, Lalot JM, Novy E, Hajage D, and Bouglé A
- Subjects
- Aged, Anti-Infective Agents pharmacology, Anti-Infective Agents therapeutic use, Female, Follow-Up Studies, Gram-Negative Bacterial Infections diagnosis, Gram-Negative Bacterial Infections mortality, Healthcare-Associated Pneumonia diagnosis, Healthcare-Associated Pneumonia mortality, Hospital Mortality trends, Humans, Male, Middle Aged, Pneumonia, Bacterial diagnosis, Pneumonia, Bacterial mortality, Retrospective Studies, Stenotrophomonas maltophilia drug effects, Treatment Outcome, Gram-Negative Bacterial Infections therapy, Healthcare-Associated Pneumonia therapy, Intensive Care Units trends, Pneumonia, Bacterial therapy, Stenotrophomonas maltophilia isolation & purification
- Abstract
Background: There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated with S. maltophilia pneumonia, focusing on antimicrobial therapy., Methods: This nationwide retrospective study included all patients admitted to 25 French mixed intensive care units between 2012 and 2017 with hospital-acquired S. maltophilia HAP during intensive care unit stay. Primary endpoint was time to in-hospital death. Secondary endpoints included microbiologic effectiveness and antimicrobial therapeutic modalities such as delay to appropriate antimicrobial treatment, mono versus combination therapy, and duration of antimicrobial therapy., Results: Of the 282 patients included, 84% were intubated at S. maltophilia HAP diagnosis for duration of 11 [5-18] days. The Simplified Acute Physiology Score II was 47 [36-63], and the in-hospital mortality was 49.7%. Underlying chronic pulmonary comorbidities were present in 14.1% of cases. Empirical antimicrobial therapy was considered effective on S. maltophilia according to susceptibility patterns in only 30% of cases. Delay to appropriate antimicrobial treatment had, however, no significant impact on the primary endpoint. Survival analysis did not show any benefit from combination antimicrobial therapy (HR = 1.27, 95%CI [0.88; 1.83], p = 0.20) or prolonged antimicrobial therapy for more than 7 days (HR = 1.06, 95%CI [0.6; 1.86], p = 0.84). No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial S. maltophilia HAP (p = 0.273). The duration of ventilation prior to S. maltophilia HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial S. maltophilia HAP (p = 0.031 and p = 0.034 respectively)., Conclusions: S. maltophilia HAP occurred in severe, long-stay intensive care patients who mainly required prolonged invasive ventilation. Empirical antimicrobial therapy was barely effective while antimicrobial treatment modalities had no significant impact on hospital survival., Trial Registration: clinicaltrials.gov, NCT03506191.
- Published
- 2019
- Full Text
- View/download PDF
44. Antibiotic prophylaxis with high-dose cefoxitin in bariatric surgery: an observational prospective single center study.
- Author
-
Belveyre T, Guerci P, Pape E, Thilly N, Hosseini K, Brunaud L, Gambier N, Meistelman C, Losser MR, Birckener J, Scala-Bertola J, and Novy E
- Abstract
Background: The optimal dose of cefoxitin for antibiotic prophylaxis in obese patients remains uncertain. We evaluated the adequacy of a 4-gram dosing regimen of cefoxitin against the most frequent pathogens that infect patients undergoing bariatric surgery., Methods: This observational prospective study included obese patients who required bariatric surgery and a 4-gram dose of cefoxitin as an antibiotic prophylaxis. Serum concentrations were measured during surgery (incision, wound closure and in case of reinjection). The pharmacokinetic/pharmacodynamic (PK/PD) target was to obtain free cefoxitin concentrations above 4× MIC, from incision to wound closure (100% ƒT
>4xMIC ). The targeted MIC was based on the worst-case scenario (the highest ECOFF value of Staphylococcus aureus , Enterobacteriaceae and anaerobic bacteria). The secondary outcomes were the factors related to underdosage., Results: Two hundred patients were included. The mean age of the patients was 46 (±12) years-old, and the mean BMI was 45.8 (±6.9) kg/m2 Bypass surgery was the preferred technique (84%). The percentages of patients who met the PK/PD target (100% f T>4xMIC ) of cefoxitin were 37.3%, 1.1% and 0% for S. aureus , Enterobacteriaceae and anaerobic bacteria, respectively. BMIs below 50 kg/m2 (OR 0.29, 95% CI [0.11-0.75], P = 0.0107 ) and a shorter duration of surgery (OR 0.97, 95% CI [0.95-0.99], P = 0.004 ) were associated with reaching the target concentrations., Conclusions: In obese patients undergoing bariatric surgery, a regimen of 4 grams of cefoxitin led to an inadequate coverage for most common pathogens. A longer surgery duration and BMI over 50 kg/m2 increase the risk of underdosage., (Copyright © 2019 American Society for Microbiology.)- Published
- 2019
- Full Text
- View/download PDF
45. Determination of 1,3-β-D-glucan in the peritoneal fluid for the diagnosis of intra-abdominal candidiasis in critically ill patients: a pilot study.
- Author
-
Novy E, Laithier FX, Machouart MC, Albuisson E, Guerci P, and Losser MR
- Subjects
- Abdomen, Aged, Cohort Studies, Critical Illness, Feasibility Studies, Female, Humans, Male, Middle Aged, Pilot Projects, Proteoglycans, Retrospective Studies, Ascitic Fluid chemistry, Candidiasis diagnosis, beta-Glucans analysis
- Abstract
Background: Decision to start an anti-fungal therapy in intra-abdominal candidiasis (IAC) is complex. Yeast culture, considered the gold standard, suffers from a delayed response time and exposes the patient to delayed introduction of anti-fungal therapy. We sought to evaluate the performance and feasibility of measuring 1,3-β-D-glucan (1,3-BDG) in the peritoneal fluid (PF) for the diagnosis of IAC., Methods: We analyzed retrospectively all PF obtained during abdominal surgery for critically ill adult patients presenting intra-abdominal infections. For each PF sample, direct examination, bacterial and fungal culture, fungal PCR and 1,3-BDG measurements were performed. The diagnostic performance of each technique and the Peritonitis score were calculated considering the positive yeast culture as the reference. The levels of 1,3-BDG were compared between IAC and non-IAC patients., Results: During an 8-month period in 2016, 33 PF samples were recovered. Median (interquartile range) SAPS 2 and SOFA scores were 44 (9-94) and 9 (4-15), respectively. There were seven cases of IAC, 14 of bacterial peritonitis and 12 of undocumented peritonitis. All IAC cases were secondary peritonitis, with a 1,3-BDG level of 1461 (325-5000) versus 224 (68-1357) pg/mL in the non-IAC group (P=0.03). When the 1,3-BDG level was ≤310 pg/mL, its negative predictive value was 100%., Conclusions: In secondary peritonitis, a peritoneal measurement of 1,3-BDG ≤310 pg/mL could rule out IAC.
- Published
- 2018
- Full Text
- View/download PDF
46. Immediate postoperative plasma neutrophil gelatinase-associated lipocalin to predict acute kidney injury after major open abdominal aortic surgery: A prospective observational study.
- Author
-
Guerci P, Claudot JL, Novy E, Settembre N, Lalot JM, and Losser MR
- Subjects
- Acute Kidney Injury epidemiology, Aged, Biomarkers, Creatinine blood, Female, Humans, Incidence, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, ROC Curve, Renal Replacement Therapy, Risk Assessment, Treatment Outcome, Acute Kidney Injury diagnosis, Acute Kidney Injury etiology, Aorta, Abdominal surgery, Lipocalin-2 blood, Vascular Surgical Procedures methods
- Abstract
Introduction: Plasma neutrophil gelatinase-associated lipocalin (pNGAL) has been used as a biomarker in acute kidney injury (AKI). AKI is a common postoperative complication of aortic surgery. We sought to evaluate the performance of the immediately postoperative pNGAL level in comparison with the serum creatinine (SCr) level in predicting AKI and the need for renal replacement therapy (RRT)., Patients and Methods: Prospective non-interventional study in a university hospital. Fifty patients undergoing elective or emergent major intra-abdominal aortic surgery were included. Comparisons between groups of patients with or without postoperative AKI, according to KDIGO staging, were made. Performance of NGAL was determined by examining the area under receiver operating characteristic (AUROC) curve., Results: The incidence of AKI was 36%. At H+2, pNGAL values in AKI and non-AKI patients, respectively, were 221 [133-278] versus 50 [50-90] ng/mL (P<0.0001), and SCr values were 115 [96-178] versus 90 [72-99] μmol/L (P<0.0008). The AUROC of pNGAL for prediction of AKI was 0.90 (95% CI: 0.81-0.98) with an optimal cutoff of 112ng/mL, a sensitivity of 83%, specificity of 84%, and positive and negative predictive values of 75% and 90%, respectively. SCr produced an AUROC curve of 0.79 (0.65-0.92) at a cutoff of 110μmol/L. The diagnostic performance of pNGAL was significantly better than that of SCr (P=0.039). PNGAL at H+2 better predicted the RRT requirement [0.96 (0.90-1.0)] compared to SCr [0.86 (0.73-0.98)], but this difference was not statistically significant., Conclusions: A 2-hour postoperative determination of pNGAL outperformed SCr level in predicting postoperative AKI after major aortic surgery., (Copyright © 2017 Société française d'anesthésie et de réanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
47. Erratum to: Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside.
- Author
-
Kimmoun A, Novy E, Auchet T, Ducrocq N, and Levy B
- Published
- 2017
- Full Text
- View/download PDF
48. Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside.
- Author
-
Kimmoun A, Novy E, Auchet T, Ducrocq N, and Levy B
- Subjects
- Acidosis, Lactic epidemiology, Acidosis, Lactic mortality, Carbon Dioxide adverse effects, Hospital Mortality, Humans, Shock epidemiology, Shock mortality, Sodium Bicarbonate therapeutic use, Acidosis, Lactic complications, Hemodynamics physiology, Shock complications
- Abstract
Lactic acidosis is a very common biological issue for shock patients. Experimental data clearly demonstrate that metabolic acidosis, including lactic acidosis, participates in the reduction of cardiac contractility and in the vascular hyporesponsiveness to vasopressors through various mechanisms. However, the contributions of each mechanism responsible for these deleterious effects have not been fully determined and their respective consequences on organ failure are still poorly defined, particularly in humans. Despite some convincing experimental data, no clinical trial has established the level at which pH becomes deleterious for hemodynamics. Consequently, the essential treatment for lactic acidosis in shock patients is to correct the cause. It is unknown, however, whether symptomatic pH correction is beneficial in shock patients. The latest Surviving Sepsis Campaign guidelines recommend against the use of buffer therapy with pH ≥7.15 and issue no recommendation for pH levels <7.15. Furthermore, based on strong experimental and clinical evidence, sodium bicarbonate infusion alone is not recommended for restoring pH. Indeed, bicarbonate induces carbon dioxide generation and hypocalcemia, both cardiovascular depressant factors. This review addresses the principal hemodynamic consequences of shock-associated lactic acidosis. Despite the lack of formal evidence, this review also highlights the various adapted supportive therapy options that could be putatively added to causal treatment in attempting to reverse the hemodynamic consequences of shock-associated lactic acidosis.
- Published
- 2015
- Full Text
- View/download PDF
49. Takotsubo Cardiomyopathy Triggered by Influenza A Virus.
- Author
-
Buzon J, Roignot O, Lemoine S, Perez P, Kimmoun A, Levy B, and Novy E
- Subjects
- Female, Humans, Influenza A Virus, H1N1 Subtype isolation & purification, Middle Aged, Takotsubo Cardiomyopathy diagnosis, Influenza A virus isolation & purification, Influenza, Human complications, Takotsubo Cardiomyopathy virology
- Abstract
We herein report the first case of Takotsubo cardiomyopathy triggered by influenza A virus. Myocardial involvement in influenza virus infection has been described in 10% of cases. The literature has principally reported cases of acute myocarditis ranging from asymptomatic to fulminant heart failure and cardiac tamponade. Takotsubo cardiomyopathy frequently occurs in the setting of significant emotional or physical stress or acute medical illness, with a predominance in postmenopausal women. We report the diagnosis, management and outcomes presented in this case, with the aim of describing a new cardiovascular complication of influenza virus infection.
- Published
- 2015
- Full Text
- View/download PDF
50. Long-term outcomes and cardiac surgery in critically ill patients with infective endocarditis.
- Author
-
Mirabel M, Sonneville R, Hajage D, Novy E, Tubach F, Vignon P, Perez P, Lavoué S, Kouatchet A, Pajot O, Mekontso-Dessap A, Tonnelier JM, Bollaert PE, Frat JP, Navellou JC, Hyvernat H, Hssain AA, Timsit JF, Megarbane B, Wolff M, and Trouillet JL
- Subjects
- Adolescent, Adult, Aged, Critical Illness, Cross-Sectional Studies, Emergency Treatment mortality, Emergency Treatment statistics & numerical data, Endocarditis mortality, Female, France epidemiology, Heart Valve Diseases mortality, Heart Valve Diseases surgery, Heart Valve Prosthesis Implantation mortality, Heart Valve Prosthesis Implantation statistics & numerical data, Humans, Immunosuppression Therapy adverse effects, Male, Middle Aged, Prospective Studies, Treatment Outcome, Young Adult, Endocarditis surgery
- Abstract
Aims: To assess long-term outcomes and the management of critical left-sided infective endocarditis (IE) and evaluate the impact of surgery., Methods and Results: Among the 198 patients included prospectively for IE across 33 adult intensive care units (ICU) in France from 1 April 2007 to 1 October 2008, 137 (69%) were dead at a median follow-up time of 59.5 months. Characteristics significantly associated with mortality were: Sepsis-related Organ-Failure Assessment (SOFA) score at ICU admission [Hazard ratio (HR), 95% Confidence Interval (CI) of 1.43 (0.79-2.59) for SOFA 5-9; 2.01 (1.05-3.85) for SOFA 10-14; 3.53 (1.75-7.11) for SOFA 15-20; reference category SOFA 0-4; P = 0.003]; prosthetic mechanical valve IE [HR 2.01; 95% CI 1.09-3.69, P = 0.025]; vegetation size ≥15 mm [HR 1.64; 95% CI 1.03-2.63, P = 0.038]; and cardiac surgery [HR (95%CI), 0.33 (0.16-0.67) for surgery ≤1 day after IE diagnosis; 0.61 (0.29-1.26) for surgery 2-7 days after IE diagnosis; 0.42 (0.21-0.83) for surgery >7 days after IE diagnosis; reference category no surgery; P = 0.005]. One hundred and three (52%) patients underwent cardiac surgery after a median time of 6 (16) days. Independent predictors of surgical intervention on multivariate analysis were: age ≤60 years [Odds ratio (OR) 5.30; 95% CI (2.46-11.41), P < 0.01], heart failure [OR 3.27; 95% CI (1.03-10.35), P = 0.04], cardiogenic shock [OR 3.31; 95% CI (1.47-7.46), P = 0.004], septic shock [OR 0.25; 95% CI (0.11-0.59), P = 0.002], immunosuppression [OR 0.15; 95% CI (0.04-0.55), P = 0.004], and diagnosis before or within 24 h of ICU admission [OR 2.81; 95% CI (1.14-6.95), P = 0.025]. SOFA score calculated the day of surgery was the only independently associated factor with long-term mortality [HR (95% CI) 1.59 (0.77-3.28) for SOFA 5-9; 3.56 (1.71-7.38) for SOFA 10-14; 11.58 (4.02-33.35) for SOFA 15-20; reference category SOFA 0-4; P < 0.0001]. Surgical timing was not associated with post-operative outcomes. Of the 158 patients with a theoretical indication for surgery, the 58 deemed not fit had a 95% mortality rate., Conclusion: Mortality in patients with critical IE remains unacceptably high. Factors associated with long-term outcomes are the severity of multiorgan failure, prosthetic mechanical valve IE, vegetation size ≥15 mm, and surgical treatment. Up to one-third of potential candidates do not undergo surgery and these patients experience extremely high mortality rates. The strongest independent predictor of post-operative mortality is the pre-operative multiorgan failure score while surgical timing does not seem to impact on outcomes.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.